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5ABSTRACT
The design and development of new screening assays in drug discovery has become increasingly
important during the past few years. Demands for high productivity have increased the need to
screen more targets with higher throughput and more information content in combination with
lower costs. To be able to meet these demands, a great deal of research is required in areas such as
target selection and in the development of improved methodologies for detection and cell-based
screens.
Miniaturised screening assays, both biochemical and cell-based, were developed and optimised for
the evaluation of biological activity against diverse targets, including protein kinase C, voltage-
gated calcium channels, Chlamydia pneumoniae and Caco-2 cells. Particular emphasis was placed
on assessment of assay quality and validation in which quality parameters such as signal-to-
background (S/B) and signal-to-noise (S/N) ratios, and screening window coefficient (Z’) were
employed. A compound library containing natural compounds and their derivatives, antimicrobial
agents as well as other known medical substances was used as a source for the model compounds
needed for screening and method validation.
Biochemical assays, a kinase activity assay and [3H]-phorbol ester binding assay were used for
primary screening of a set of compounds to establish their potential inhibitory effects on protein
kinase C (PKC). The most potent inhibitors of kinase activity were (-)-epigallocatechin gallate and
(-)-epicatechin gallate. In addition, dodecyl gallate, and the flavonoids myricetin, quercetin,
rhamnetin, luteolin, isorhamnetin and kaempferol also had significant effects on PKC activity.
However, no marked inhibition of the binding of phorbol ester to the regulatory domain of PKC?
was observed, suggesting that the mechanism of PKC inhibition could be the result of binding to
the catalytic domain of PKC. The suitability of these PKC assays for screening was demonstrated
by the excellent values obtained for assay repeatability, reproducibility and quality parameters.
A 45Ca2+ uptake assay based on clonal rat pituitary cell line GH4C1, possessing L-type voltage-
operated calcium channels, was miniaturised into a 96-well plate format and optimised to improve
performance and cost effectiveness. The validity of the assay was demonstrated by the fact that the
results were consistent with previous data from Petri dish assays and by the high assay quality.
Miniaturisation resulted in considerable savings in time, labour and resources, and the suitability of
the assay for automation was demonstrated on a Biomek FX workstation, thus further improving
the applicability of this assay for screening programmes. The automated 45Ca2+ uptake assay was
also successfully coupled with HPLC micro-fractionation for primary detection of calcium
antagonistic components in complex matrices shown with a root extract of Peucedanum palustre,
significantly reducing the time needed for bioactivity-guided isolation of active compounds.
A novel time-resolved fluorometric immunoassay (TR-FIA) was developed and validated for
susceptibility testing of Chlamydia pneumoniae. By constructing a europium-labelled antibody we
were able to design a cell-based, 96-well plate assay where chlamydial inclusions can be quantified
as time-resolved fluorometric signals by means of a multilabel counter. Minimum inhibitory
concentrations (MIC) measured using the TR-FIA demonstrated good to excellent correlation with
those of two reference methods, immunofluorescence staining and real-time PCR. TR-FIA also
offers the possibility for simultaneous cytotoxicity assessment by means of dual labelling with a
protein dye, sulphorhodamine B. This novel assay significantly facilitates the laborious
6methodology needed for the detection of intracellular bacteria and eliminates the subjectivity of
traditional staining methods.
The ability of compounds to interact with biomembranes and cellular permeability is of great
importance during the screening process. In this study, a set of flavonoids and alkyl gallates were
studied using transport studies on Caco-2 cells and membrane affinity experiments in phospholipid
vesicles. The apparent permeability coefficients (Papp) from the Caco-2 and the partition
coefficients (Kd) from the membrane affinity experiments yielded similar information on the
biomembrane interactions of flavonoids, showing that strong membrane affinity was generally
accompanied by poor apical to basolateral transport in Caco-2 cells. Therefore, in this case the
biochemical membrane affinity assay would have been a good predictor of a compound’s
permeability characteristics in Caco-2 cells, and could be a useful, less laborious tool for
eliminating compounds with undesirable permeability characteristics from large compound pools.
In conclusion, the design of a screening assay is an array of multiple choices, all of which have
significant impacts on the outcome of the overall drug discovery process. Most importantly, the
correct selection of the target and assay format, detailed optimisation and miniaturisation as well as
the choice of appropriate detection technology for each individual assay can lead to savings in time,
money and labour along with improved data quality in all stages of the drug discovery process. The
knowledge gained in this study on assay development, miniaturisation and automation has provided
important and useful information for setting up bioactivity screening programmes in academic
settings.
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8ABBREVIATIONS
A absorption of photons
ADME absorption, distribution, metabolism, excretion
ADMET absorption, distribution, metabolism, excretion, toxicology
ADP adenosine diphosphate
ATCC American Type Culture Collection
ATP adenosine triphosphate
BRET bioluminescence resonance energy transfer
Caco-2 human colon adenocarcinoma cell line
cAMP cyclic 3’,5’-adenosine monophosphate
CNS central nervous system
3D 3-dimensional
DAD diode array detector
DMSO dimethylsulphoxide
DNA deoxyribonucleic acid
DTPA diethylenetriaminepentaacetic acid
DTTA diethylenetriaminetetraacetic acid
EB elementary body
EMEA European Agency for the Evaluation of Medicinal Products
Eu europium
F fluorescence
FCS fluorescence correlation spectroscopy
FDA US Food and Drug Administration
FI fluorescence intensity
FIDA fluorescence intensity distribution analysis
FL fluorescence lifetime
FLIM fluorescence lifetime imaging microscopy
FP fluorescence polarisation
FRET fluorescence resonance energy transfer
GFP green fluorescent protein
GH4C1 clonal rat pituitary gland cell line
GPCR G protein-coupled receptor
HBSS Hanks’ balanced salt solution
HCS high-content screening
HIV human immunodeficiency virus
HL cell line originating from the human respiratory tract
HPLC high-performance liquid chromatography
HRS high-resolution screening
HTS high-throughput screening
IAM immobilized artificial membrane
IC internal conversion
IC50 concentration yielding 50% inhibition
IF immunofluorescence
IFU inclusion-forming unit
ISC intersystem crossing
Kd partition coefficient
LC liquid chromatography
9LDH lactate dehydrogenase
luc luciferase gene
MCH melanin-concentrating hormone
MIC minimum inhibitory concentration
MS mass spectrometry
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
NAD nicotinamide adenine dinucleotide
NCE new chemical entity
P phosphorescence
Papp apparent permeability coefficient
PAMPA parallel artificial membrane permeation assay
PCR polymerase chain reaction
PKA protein kinase A
PKC protein kinase C
PKC? protein kinase C isoform ?
PMA phorbol 12-myristate 13-acetate
POPC 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine
RNA ribonucleic acid
S singlet state
SAR structure-activity relationship
S/B signal-to-background
Sf9 insect cell line derived from Spodoptera frugiperda
S/N signal-to-noise
SPA scintillation proximity assay
SRB sulphorhodamine B
T triplet state
TEER transepithelial electrical resistance
TRET time-resolved energy transfer
TRF time-resolved fluorometry
TR-FIA time-resolved fluorometric immunoassay
uHTS ultra-high-throughput screening
UV ultraviolet
Vis visible
VOCC voltage-gated calcium channel
Z screening window coefficient calculated from library sample data
Z’ screening window coefficient calculated from control sample data
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1. INTRODUCTION
The discovery of a new drug is a long and expensive process. From the synthesis of a compound to
its approval can take 10-20 years, with an estimated average of about 9-12 years (Dickson and
Gagnon 2004). A recent survey of 68 randomly selected new drugs yielded a total pre-approval
cost estimate of 802 million US dollars for the research and development costs when unsuccessful
projects were also included (DiMasi et al. 2003). Considering the fact that the preclinical costs per
approved new drug account for more than 40% of the total costs and yet only 21.5% of new
chemical entities (NCE, a new therapeutic molecule or compound that has not been tested on
humans) that begin Phase I human trials are eventually brought to market, optimisation in the early
stages of drug discovery would benefit both the industry and the consumer (DiMasi et al. 2003,
Frank 2003, Ng and Ilag 2004).
For decades, bioactivity screening has been an integral part of the modern drug discovery process.
The progress made in biochemistry, genomic sciences, combinatorial chemistry, etc. gave rise to
the establishment of high-throughput screening (HTS) technologies (Drews 2000). The demand for
higher productivity has increased the need to screen more targets with higher throughput and lower
costs. From the mid-1990’s major investments have been made in automated systems and novel
technologies, and these have led to significant improvements in the speed, capacity and costs of
HTS programmes. At the beginning of the 1990s, the number of data points generated by large
screening programmes at a pharmaceutical company amounted to roughly 200,000 and rose to 5 to
6 million by the mid-decade (Drews 2000). Currently, in typical ultra-high-throughput screening
(uHTS) campaigns 500,000 to 2 million compounds can be screened in 1-3 weeks with more than
100 targets per year.
Despite the advances and investments in drug discovery technologies during the past decade, there
has been no improvement in productivity in terms of the approval of NCEs (Schmid and Smith
2004). The number of new products reaching the market is still declining: in 2002, the US Food
and Drug Administration (FDA) approved only 18 new molecular entities and the European
Agency for the Evaluation of Medicinal Products (EMEA) only 13 new medicinal products (Frantz
and Smith 2003). It has been argued that too much attention has been focused on the number of
compounds that could be assayed using HTS, with insufficient critical evaluation of the quality of
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the data generated, particularly in regard to interaction specificity and predictive absorption,
distribution, metabolism, excretion and toxicology (ADMET) (Cooper 2003).
The unfulfilled expectations placed on HTS and the high failure rate of discovered NCEs are
probably the main driving forces behind the current industry-wide shift towards cell-based
screening, which produces biologically more relevant information starting from the early stages of
drug discovery (Johnston and Johnston 2002). It is noteworthy that many of the successful drugs on
the market today were identified 30-40 years ago using traditional pharmacological approaches, i.e.
functional cell-based assays, which can be seen as an advocate for the change towards using
cellular assays in HTS (Moore and Rees 2001). Due to recent advances in assay technology,
instrumentation and automation, the use of mammalian cell-based assays has expanded to all stages
of the lead generation process, including primary screening. Increasing attention has been given to
assay design and quality in all aspects of bioactivity screening such as target identification and
validation, detection technologies and assay automation. Novel screening approaches tend to move
towards high-content screening (HCS) through in-depth use of bioinformatics, computational
methods for the filtering and focusing of compound libraries, and automated fluorescence
microscopy imaging (Entzeroth 2003, Walters and Namchuk 2003). The definitive goals in modern
HTS are lower cost and higher information content, leading from hits to high-quality lead
compounds.
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2. REVIEW OF THE LITERATURE
2.1. The process of generating lead compounds
The drug development process has been described as a multi-stage, multi-period set of choices
(DiMasi et al. 2003). The lead generation alone consists of diverse sectors that require
interdisciplinary experience, i.e. extensive knowledge in the fields of pharmacology, biochemistry,
molecular biology, chemistry, engineering, etc. (Fig. 1). The initial step in drug discovery involves
the identification and validation of a target, commonly a disease-linked protein, usually stemming
from the genome, modulation of which is predicted to produce the desired effect. The design and
development of a screening assay for the evaluation of activity is of the utmost importance in the
process. The selected assay should be designed to examine the target activity with high sensitivity
and specificity in a setting that mimics the in vivo dynamics as far as possible. The decisions made
in assay design are governed by several factors, including the nature of the target and the
pharmacological information sought. The resulting assay and data quality is significantly affected
by the choice made between the different available detection technologies and assay formats. The
implementation of HTS strategies, including miniaturisation and adequate automation, sets further
criteria for the assay. The identification of hit candidates generally involves screening of
collections of compounds or natural products, and hits enter an array of secondary screens,
typically designed to evaluate the biological activity in more complex assay systems to confirm the
activity observed in primary screening. The preclinical follow-up evaluation of hits includes
analysis of compound efficacy and pharmacology, and studies of toxicology, specificity,
biopharmaceutical properties and drug interactions from many aspects. Based on these criteria, hit
compounds are selected for optimisation by synthetic chemistry and for more extensive preclinical
evaluation in progressively more complex systems, from cells to whole organisms. In the lead
optimisation phase, the hit molecule obtained from HTS is subjected to methodological synthetic
modification by medicinal chemists in order to optimise the compound characteristics, including its
activity and ADMET profile. The preclinical data forms the basis for the pharmacology section of
an investigational new drug application to carry out clinical trials. (Lipsky and Sharp 2001,
Bleicher et al. 2003, Dove 2003, Kenakin 2003, Knowles and Gromo 2003, Verkman 2004)
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Figure 1. The lead generation process (SARs = structure-activity relationships) (adapted from
Johnston and Johnston 2002).
2.2. Target identification and validation
The basis for screening assay development is a good, validated target. It has been estimated that 30-
40% of experimental drugs fail because an inappropriate biological target was pursued (Butcher
2003). In target validation, the ultimate objective is to establish a crucial role for the molecular
target in question in the cause or symptoms of a human disease (Williams 2003). To be judged as
validated, genetic or pharmacological manipulation of a target should consistently lead to
phenotypic changes that are in line with the desired effect in a dose-dependent manner. The desired
changes must also be inducible in at least one relevant animal model, reflecting aspects of the
human pathogenesis of the respective disease. In addition, the way in which the manipulation of a
target molecule leads to a particular phenotype should be recognised, and whether or not other gene
products are involved, with the possible attendant danger of toxic side effects (Drews 2003).
The recent publication of the human genome (Lander et al. 2001, Venter et al. 2001) revealed the
presence of 30,000-40,000 genes on human chromosomes leading to an overabundance of possible
drug targets. The present number of known and well-validated drug targets is, however, relatively
COMPOUNDS ACTIVES HITS LEADS
HTS FOLLOW-UP VALIDATION
Assay development
Target identification and validation
Genomics, proteomics and molecular biology
Automation
Natural
 products
Chemistry
Combinatorial
synthesis
Structural
verification
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small. About 3,000 genes of the human genome belong to so-called drug-target families, but only a
small minority of these genes are related to targets that are actually affected by pharmaceutical
compounds. According to recent estimates, only less than 500 drug targets are involved in the
mechanism of action of currently known drugs (Drews 1996, Drews 2000, van Duin et al. 2003).
The number may actually be even smaller: a recent review identified only 120 targets for all
marketed drugs (Hopkins and Groom 2002). However, it has been estimated that there are 500,000
different proteins, or potential points of pharmacological intervention, in the human body (Davies
et al. 2004).
Selecting a target can be approached from several different angles. The gene pool can be filtered by
concentrating on the prime candidate gene families encoding G protein-coupled receptors (GPCR),
nuclear receptors, ion channels and kinases or on the orphan targets of these families (Butcher
2003, van Duin et al. 2003). Novel targets can be pursued by using genotyping of patient tissues or
by manipulating the activity of the potential target protein itself using a proteomics approach
(Sundberg et al. 2000). Another way to target validation is to disrupt the gene expression to reduce
the amount of the corresponding protein. This can be achieved using antisense technology,
ribonucleic acid (RNA) interference and genetic knockouts (Harris 2001, Butcher 2003, Smith
2003, Williams 2003). In the chemical genomics approach, the function of an unknown target can
be defined by finding high-affinity binders to that target to determine what effects the binding has
on intact cellular systems (Williams 2003). Recent progress in drug discovery has seen a realisation
of the limitations of genomics, proteomics or other approaches per se, and the focus has shifted to
using a unified approach to address the different aspects of target validation, e.g. by combining
protein-interaction mapping of biological pathways with corresponding target information of
known small-molecule compounds showing efficacy (Brown and Superti-Fuga 2003, Ng and Ilage
2004) or by using a multiple orthogonal tools approach where several tools are combined so that
the target and the candidate therapeutic agent can be varied orthogonally independently of each
other (Fig. 2) (Hardy and Peet 2004). However, despite all the efforts made in the early stages of
drug discovery, target validation is only conclusive when the drug has finally been shown to be
effective in the targeted human disease (Williams 2003).
15
Figure 2. The multiple orthogonal tools approach in target validation (modified from Hardy and
Peet 2004).
2.3. Sources for lead compound discovery
Novel medicinal lead compounds are sought by assaying large compound collections. When these
screening libraries are being designed structural diversity is the main principle pursued (Nilakantan
and Nunn 2003). Compounds for the libraries can be created by combinatorial chemistry or
searched from natural sources. Focused libraries can be constructed by combining combinatorial
chemistry with structure-based drug design, which involves the use of the 3-dimensional (3D)
structure of a target protein, or a theoretical model obtained from homology modelling, to study the
interactions between potential lead compounds and the target. However, the diversity offered by
compounds produced by combinatorial chemistry is limited compared to compounds derived from
natural products (Strohl 2003). According to Newman et al. (2003), during the period 1981-2002
no de novo combinatorial compound approved as a drug could be identified. In fact, the power of
combinatorial chemistry lies mostly in optimising compound characteristics such as absorption,
distribution, metabolism and excretion (ADME) profile, in all phases of drug discovery.
During the 1990’s the progress made in developing techniques for combinatorial chemistry led to
diminished interest in natural products, which were considered unsuitable for modern HTS
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(Simmonds 2003), and the use of natural products as sources of new leads was widely disregarded.
Yet, for decades the majority of drugs have been discovered from natural products: 61% of the 877
small-molecule new chemical entities introduced as drugs worldwide during 1981-2002 can be
traced to, or were inspired by, natural products (Newman et al. 2003). Additionally, biologically
active natural products are generally small molecules with drug-like properties, capable of being
absorbed and metabolised by the body (Harvey 2000). Lately this potential has again been realised
in screening programmes, which has led to the increased exploitation of natural sources. In fact,
strategies have been described for the overall process of finding active components from nature
(Vuorela et al. 2004).
Interest in screening natural sources for new leads has also grown because certain practical
difficulties in separation technologies and in the speed and sensitivity of structure elucidation have
been overcome in the case of natural products (Hostettmann et al. 2001). Active components can
now be identified direct from complex mixtures such as extracts employing a high-resolution
screening (HRS) approach, which includes chromatographic separation followed by on-line
biochemical detection parallel with chemical characterisation (Schenk et al. 2003). As an example,
Danz et al. 2001 have been able to identify on-line the cyclooxygenase-2 inhibitory principle in
Isatis tinctoria using a hyphenated technique of liquid chromatography (LC) with a diode array
detector (DAD) and mass spectrometry (MS) in combination with a microtitre-based bioassay. On
the other hand, high-throughput techniques developed for combinatorial chemistry can be utilised
to generate large libraries of purified fractions of small-molecule natural products, further enabling
the reintroduction of natural products as an important source for drug discovery (Eldridge et al.
2002).
Historically, the mostly exploited natural source has undoubtedly been the plant kingdom, which
still offers major opportunities as less than 5% of existing plant species have been chemically
examined so far. The second most successful natural source has been fungi, from which
breakthroughs like antibiotics, immunosuppressants and anticancer drugs have been discovered.
Recently, much attention has also been given to less conventional natural sources including
organisms of marine origin (Harvey 2000, Tulp and Bohlin 2004).
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2.4. Assay design and development
The conversion of a biological target into a screening assay requires not only an understanding of
the biology and biochemistry underlying both the disease and the readout of the assay but also an
understanding of the other components involved in HTS, including automation strategies (Bronson
et al. 2001). Assay design is based on the chosen target and depends mostly on the nature of the
target and on the type of information sought, but also on the availability of reagents and plate
readers, on the adaptability to miniaturisation and automation as well as on the stage of the project
in the drug discovery process (Moore and Rees 2001, Seethala 2001). One of the most important
issues in developing a cost-effective HTS method is the low cost and easy production of the target.
Assay formats employed in screening can be basically divided into two main categories: cell-based
and biochemical, i.e. isolated target screens (enzymes, receptors, etc.). Both formats have
undoubted value, and usually a number of factors influence the choice of format (Johnston and
Johnston 2002). One of these factors is the size of the library to be screened, i.e. uHTS programmes
are typically based on biochemical screens. Basically, to be suitable for HTS, an assay must be
robust, reproducible, and automatable (Bronson et al. 2001).
The current trend in drug discovery is clearly shifting towards cell-based assays starting from the
primary screening stage. The advantages of cell-based screening are multiple. Most importantly,
cell-based functional assays can provide biologically more relevant information on the compound’s
activity at a receptor or ion channel, and on the nature of this activity, information that cannot be
achieved from a biochemical assay. Some targets may not be adequately configured in a
biochemical assay due, for instance, to complex interactions between receptors and other cellular
elements (Moore and Rees 2001, Johnston and Johnston 2002). In addition, cellular assays can
simultaneously yield information on compound cytotoxicity and cellular membrane permeability.
In fact, pharmaceutical companies have also started to screen drug candidates as early as possible
for predictive in vitro indicators of in vivo activity and bioavailability, e.g. permeability in human
colon adenocarcinoma (Caco-2) cell culture model, to reduce the number of compounds advancing
to the traditional, more time-consuming secondary assays (Withington 2002, Cooper 2003). With
most cell-based screens the logistics are more challenging than with biochemical screens, and
significant assay development and investments in cell culture infrastructure are required (Moore
and Rees 2001). Of importance is also the selection of cell line to be used, preferably with stable,
18
high-level expression of the target. In most cases, cellular assays are not yet amenable to uHTS
(Boguslavsky 2004b). The compound’s cytotoxicity can also mask its activity at the target, the
result being false positives or negatives (Johnston and Johnston 2002).
The pursuit of cost savings through assay miniaturisation has resulted in the development and
increasing use of homogeneous assay formats (so-called ‘mix and measure’ assays) which require
only a series of additions without any separation steps (Bosse et al. 2000). Homogeneous assays
enable the use of high-density well formats reducing the requirements set for performing the assay,
e.g. by using automated liquid handling. Most homogeneous assays involve isolated targets and are
fluorescence-based, but cellular assays have also been recently employed in homogeneous format,
e.g. reporter assays based on green fluorescent protein (GFP) (Seethala et al. 2001).
Lately, approaches have evolved to increase the data content and quality from HTS. The term
‘high-content screening’ (HCS) summarises cellular assays based on sub-cellular imaging and
automated image analysis (Gribbon and Sewing 2003). Work is also being done to obtain multiple
data points from a single well of a plate by employing multiplexed and multi-parametric assay
formats. The former are assays that produce a single measurement for each multiple cell type
within a single well, and the latter yield multiple measurements from a single cell type (Beske and
Goldbard 2002). An assay measuring multiple parameters has been described for instance for the
evaluation of apoptosis by Lövborg et al. (2004) who were able to measure simultaneously the
caspase-3 activity using fluorescein-tagged probes, mitochondrial membrane potential by
chloromethyl-X-rosamine and nuclear morphology by deoxyribonucleic acid (DNA)-binding dye.
A multi-parametric homogeneous time-resolved fluorescence quenching-based assay capable of
detecting the activity of three caspases in a single well by using chelates of europium, samarium
and terbium has also been reported (Karvinen et al. 2004).
Multiplexing cell-based assays is providing new potential for cell-based screening by enabling
investigation of multiple targets simultaneously and the possibility of including controls within
each well (Martins 2002). Obviously, certain limitations are involved, e.g. the need for similar
culture requirements for the cell lines and possible cellular cross-talk (Beske and Goldbard 2002).
Multiplexing has been successfully exploited in studying the agonists of nuclear receptors (Grover
et al. 2003) as well as in developing an HTS platform for protein-protein interactions using a
luciferase-based assay (Nieuwenhuijsen et al. 2003). Thus, in addition to increasing assay
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throughput by incorporating low volume, high-density formats, further improvements can be made
through the use of multiplexing and multi-parametric strategies.
Once a suitable assay format and design have been chosen, detailed refinement is needed to ensure
that the assay is robust and consistent throughout the screening programme. In enzymatic assays,
optimisation and validation for HTS involves steps addressing reaction conditions (buffers, pH,
ionic strength, temperature), substrates (natural and synthetic), enzyme source and kinetics,
estimation of signal windows and the responses of known inhibitors (Bronson et al. 2001). All
reagents from plates and chemicals to biological material should be examined for lot-to-lot
variability and stability. In cell-based assays, particular attention should be given to the
characterisation of cellular growth under different conditions, and optimal cell seeding densities,
cellular adherence to microplates, dimethylsulphoxide (DMSO) tolerance and within-in-plate
variation in the signal during long-term incubations also need to be determined (Moore and Rees
2001, Johnston and Johnston 2002). Particularly in cell-based assays, the creation of precise
operational procedures becomes necessary because of the sensitivity of most cell lines to alterations
in properties due to small changes in environmental conditions. The signal reproducibility and the
robustness of the signal window should also be examined, and this data is typically used to
establish an active criterion for the HTS during assay development (Johnston and Johnston 2002).
Following optimisation, an assay should be validated to ensure its consistency in the quantitative
determination of active compounds (Bronson et al. 2001).
2.5. Detection technologies
Advances in technology during the past few years have led to the emergence of a variety of
detection technologies for use in screening assays. In particular, fluorescence detection is more and
more exploited as assay readouts, although methods based on radioactive isotopes are also still
widely used. The trend towards the use of non-radioactive labels is the result of health and safety
concerns, other factors being cost-effectiveness and the avoidance of generating radioactive waste
(Bronson et al. 2001). However, problems are also related to the detection of fluorescence signals:
the signal can be subject to quenching by compounds, plastics or media, fluorescence emissions
can be scattered by particulates, or the signal can be masked by autofluorescence (from protein or
compounds) or by high background fluorescence from unbound labelled probes (Rogers 1997). The
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detection modalities typically utilized in HTS and drug discovery can be divided into four main
categories: 1) fluorometric, 2) radiometric, 3) luminometric, and 4) photometric detections. The
following chapters will give short descriptions of all these categories.
2.5.1. Fluorometric detection
Fluorescence occurs when photons of light absorbed by a molecule (in ~ 10-15 s) cause electrons to
become excited to a higher electronic state and to return to the ground state after approx. 10-8 s with
emission of light energy. The light emitted has a longer wavelength than that absorbed (the Stokes
shift) as a result of a small dissipation of energy during the excited state (Lakowicz 1983, Emptage
2001). Fluorescence can be schematically illustrated by a Jablonski diagram (Fig. 3), first proposed
by prof. A. Jablonski (1933) to describe the absorption and emission of light. Prior to excitation the
electronic configuration of a molecule is defined as being the ground state. Once a molecule has
been excited to a higher energy and vibrational state, there are a number of routes by which the
electron can return to the ground state: if the photon emission occurs between the same electron
spin states this is termed fluorescence, and if the spin states of the initial and final energy levels are
different, the emission is called phosphorescence.
Figure 3. The Jablonski diagram. A = absorption of photons, F = fluorescence, P =
phosphorescence, S = singlet state, T = triplet state, IC = internal conversion, ISC = intersystem
crossing (modified from Jablonski 1933 and Lakowicz 1983).
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In an attempt to improve the characteristics of fluorometric detection, multiple modifications have
been created and used for diverse assay formats including homogeneous and cell-based assays.
These modifications can be categorised as 1) fluorescence intensity (or prompt fluorescence, FI), 2)
fluorescence polarisation/anisotropy (FP), 3) fluorescence resonance energy transfer (FRET), 4)
fluorescence lifetime (FL), 5) time-resolved fluorescence (TRF) and 6) single-molecule detection
methods, such as fluorescence intensity distribution analysis (FIDA) and fluorescence correlation
spectroscopy (FCS) (Hemmilä and Hurskainen 2002, Gribbon and Sewing 2003).
Fluorescence intensity (FI). The simplest form of fluorescence, FI, typically utilises fluorescent
enzyme substrates and indicators loaded into membranes or compartments that alter their intensities
due to environmental change (González and Negulescu 1998, Pope et al. 1999). The measured
steady state FI is linearly related to changes in fluorophore concentrations. A well-known example
of intensity-based indicators for cell-based assays is Fluo-3, a fluorescein-based Ca2+ sensor whose
FI increases approx. 100-fold upon binding Ca2+ (Minta et al. 1989). Owing to the simple
methodology, FI is widely used, although it is also very much affected by compound quenching,
autofluorescence effects and inner-filter phenomena (Pope et al. 1999, Gribbon and Sewing 2003).
Recently, the use of FI has been described in measuring the enzyme activity of several protein
phosphatases (phosphoserine/phosphothreonine phosphatases and phosphotyrosine phosphatases),
which are critical components in cellular regulation (Kupcho et al. 2004). This homogeneous
application exploits fluorogenic peptide substrates (rhodamine 110, bis-phosphopeptide amide) that
do not fluoresce in their conjugated form; however, upon dephosphorylation by the phosphatase of
interest, the peptides become cleavable by the protease and release the highly fluorescent free
rhodamine 110. In this work, FI was used as a detection method in the real-time polymerase chain
reaction (PCR) of Chlamydia pneumoniae and in the microscopic visualisation of chlamydial
inclusions by using a fluorescein isothiocyanate-labelled antibody [IV].
Fluorescence polarisation (FP). In FP experiments the excitation light is typically polarised and
emission is measured in parallel and perpendicular orientations (Pope et al. 1999). The polarisation
of the emitted light depends on how far the fluorophore rotates during the lifetime of its excited
state. FP measures the rotation of single biomolecules or their complexes by interrogating the
relative polarisation state of emitted fluorescence, i.e. the smaller the molecule, the faster it rotates,
and the smaller its FP will be. Binding of a fluorescence-labelled ligand to its receptor in solution
or on the surface of a living cell will result in slower rotation and an increase in FP (Rogers 1997,
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Gribbon and Sewing 2003). FP is a ratiometric technique, and hence less prone to interference from
inner-filter effects. It is also more tolerant to fluorescence quenching (for example by compounds,
plastics, or media) and light scattering (Rogers 1997, Pope et al. 1999). Owing to the volume-
independence of the polarisation signal and its rapidity due to homogeneous technology, FP is
extensively used in HTS and several applications have been described. FP is typically exploited in
assays to monitor hydrolytic or binding reactions (Pope et al. 1999). FP applications include a high-
throughput screen to identify novel ligands of FK506 (immunosuppressive compound) binding
protein 12 , which may have a role in neuronal survival (Bollini et al. 2002), as well as for the
identification of inhibitors of heat shock protein 90, a molecular chaperone with essential functions
in maintaining transformation (Kim et al. 2004).
Fluorescence resonance energy transfer (FRET). Fluorophore pairs, or FRET pairs (donor and
acceptor), with overlapping emission and excitation spectra are utilised in FRET. The excitation
energy is transferred from a donor fluorophore to an acceptor via a dipole-dipole vectorial coupling
when the acceptor is in close proximity to the donor (1-5 nm) (Wu and Brand 1994, Gribbon and
Sewing 2003). In FRET experiments the ratio of donor and acceptor emission intensities is
recorded, which makes the method minimally prone to variations in cell number, probe
concentration or optical paths and results in improved reproducibility and signal-to-noise ratio. On
the other hand, the spectral overlap between the emissions of donor and acceptor can reduce the
dynamic range of the assay, and FRET changes can be limited by non-optimal fluorophore
orientations or spacing (González and Negulescu 1998). FRET has been used for measuring the
binding of inhibitors to stromelysin, which is involved in cancer, arthritis, restenosis, and other
diseases that are caused by or result in the degradation of connective tissue matrices (Epps et al.
1999, Stetler-Stevenson et al. 1993). Recently, an HTS assay based on FRET has been described
for screening of small-molecule inhibitors of prokaryotic ribosome assembly to identify lead
compounds for potential antimicrobials (Klostermeier et al. 2004).
Fluorescence lifetime (FL). The lifetime of a fluorescent probe, i.e. the average time the electrons
spend in the excited state, can be used as a directly determined output parameter in HTS systems
(Turconi et al. 2001, Gribbon and Sewing 2003). FL can be measured by illuminating the sample
with a modulated continuous light wave, and the phase shift between the modulation of the
excitation light and the emission of the fluorescence can be used to calculate the lifetime
(frequency-domain FL). Alternatively the sample can be illuminated with a laser and the time-
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dependent decay of the fluorescence intensity measured (time-domain FL) (Lakowicz 1983). FL is
based on the intrinsic molecular property of the fluorophore that is not influenced significantly by
light scattering in biological matter (Weber 1981, Lakowicz 1983, Wild 1977, Hovius et al. 2000).
FL is able to detect minute changes in the fluorophore’s immediate environment: a change in
molecular brightness induced, for example, by a binding process results in a change in total
fluorescence intensity and lifetime. FL is increasingly being used in HTS because of its sensitivity
and robustness (Lakowicz 1983, Eggeling et al. 2003). However, changes in FL are not always
predictable, and this limits the applicability of FL in biological reactions (Eggeling et al. 2003). To
image molecular interactions in live cells, FL is exploited in fluorescence lifetime imaging
microscopy (FLIM), which can provide information not only concerning the localisation of specific
fluorophores, but also about the local fluorophore environment (Hovius et al. 2000). FLIM has
been successfully exploited in studying the receptor tyrosine kinase activity in cells (Wouters et al.
1999), protein kinase C (PKC) regulation mechanisms (Ng et al. 1999), and to detect
intermolecular FRET in living neurones (Duncan et al. 2004).
Time-resolved fluorescence (TRF). TRF exploits fluorophores with long fluorescence lifetimes,
such as rare earth elements like europium, samarium and terbium. As such, these lanthanides
exhibit a very weak absorption of excitation energy and are poor fluorophores. In order to improve
the collection of excitation energy, lanthanides are normally chelated with a ligand, e.g.
diethylenetriaminetetraacetic acid (DTTA) or diethylenetriaminepentaacetic acid (DTPA), which is
able to absorb excitation light and transfer the energy to the ion (Hemmilä and Harju 1994). The
unique fluorescence properties of lanthanide chelates allow temporal resolution of the signal from
the short-lived fluorescence caused by background interference (e.g. sample/reagent fluorescence,
luminescence of plastics and optics), i.e. the signal can be measured once non-specific background
fluorescence has decayed (Soini and Kojola 1983, Hemmilä et al. 1984). Other fluorescence
properties of lanthanides, e.g. a substantial Stokes’ shift (difference between excitation and
emission peaks) and the narrow emission peak, contribute to increasing the signal-to-noise ratio.
The sensitivity is further increased by the dissociation-enhancement principle, which means that
the lanthanide is dissociated into a new highly fluorescent chelate inside a protective micelle.
Lanthanide chelates can be used for protein, peptide and oligonucleotide labelling, and europium,
which was first applied by Hemmilä and co-workers as a tool for immunofluorometric assays
(Hemmilä et al. 1984), is frequently used for labelling antibodies. TRF is extensively employed in
various applications, e.g. for studying leukocyte adhesion (Saarinen et al. 2000), for cytotoxicity
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screening (Blomberg et al. 1986, Bouma et al. 1992), for measurement of interferon activity in
relation to human cells (Trinh et al. 1999), and for identifying cyanovirin-N [a potent anti-human
immunodeficiency virus (HIV) protein] mimetics among natural product extracts (McMahon et al.
2000). Applications in which TRF is used in combination with FRET (time-resolved energy
transfer, TRET) have also emerged, examples being the identification of inhibitors of viral and
bacterial helicases in 96- and 384-well plate formats (Earnshaw et al. 1999) and the detection of
insulin receptor tyrosine kinase activity (Biazzo-Ashnault et al. 2001). In these experiments
europium-labelled antibody has been employed as the donor and XL665-labelled streptavidin as the
acceptor. In the present study, time-resolved fluorometric immunoassay exploiting europium-
labelled antibody was developed for the evaluation of antichlamydial activity [IV].
Fluorescence intensity distribution analysis (FIDA) and fluorescence correlation spectroscopy
(FCS). FIDA and FCS are based on the analysis of temporal fluctuations in the fluorescence signal
detected from the spontaneous diffusion of individual fluorescent molecules into and out of a small,
tightly focused confocal element. These techniques allow the determination of concentrations and
specific brightness values of individual fluorescent species in a mixture (Ehrenberger and Rigler
1974, Auer et al. 1998, Kask et al.1999, Pope et al. 1999). In FCS, it is the diffusion characteristics
and concentration of fluorescent molecules that are determined (Eigen 1994, Maiti et al. 1997),
whereas in FIDA the amplitude information in the fluctuation signal is used to determine the
fluorescence intensity and concentration of fluorescent molecules (Kask et al. 1999). These single-
molecule detection methods can be applied for biochemical assays if the fluorescent analyte
undergoes a change of brightness. The signal output in FIDA and FCS is independent of the total
assay volume, making these techniques especially useful in HTS and uHTS (Pope et al. 1999). As
examples, changes in fluorescence intensity measured by FIDA have been employed in measuring
the enzyme activity of phosphotyrosine kinase, protease and alkaline phosphatase as well as the
interactions of fluorescent-labelled ligands with a range of GPCRs, e.g. the binding of melanin-
concentrating hormone (MCH) to MCH receptor (Rüdiger et al. 2001, Haupts et al. 2003).
2.5.2. Radiometric detection
In radiometric experiments, radioactive labels are employed to measure the biological activity of
interest. These labels are usually produced by substituting an existing atom of a compound with its
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radioisotope, e.g. 14C, 3H, 32P or 125I. The presence of the radioactive compound can be measured
by scintillation counting, in which the disintegration of the radioisotopic labels is quantified as
particles emitted by the label (Aalto et al. 1994). The most important applications of radiometric
measurement are in immunoassays, DNA hybridisation, receptor binding and cellular assays as
well as metabolic studies (Hemmilä 1994). Radioactive labels have been gradually replaced by
other labels, such as fluorescent and luminescent molecules, due to their disadvantages, which
mostly relate to health and waste problems.
For HTS, however, a special assay format called scintillation proximity assay (SPA) that uses
radiometric detection has been created (Udenfriend et al. 1987). SPA employs a scintillant
embedded within a microbead matrix (or alternatively onto the surface of a microtitre plate) coated
with a capture molecule (e.g. streptavidin or glutathione) to immobilise the target of interest. SPA
provides an opportunity to measure ligand binding interactions (Bronson et al. 2001). When a
radiolabelled ligand binds to its target on the surface of the bead, the radioactive decay occurs in
close proximity to the bead. The energy is effectively transferred to the scintillant, resulting in the
emission of light. When the radiolabel is displaced or inhibited from binding to the bead, it remains
free in solution and is too distant from the scintillant for efficient energy transfer. Energy from
radioactive decay is dissipated into the solution, which results in no light emission from the beads.
Hence the bound and free radiolabel can be detected in homogeneous assay format without the
physical separation required in filtration assays (Sittampalam et al. 1997b). Recently, applications
exploiting SPA have studied the inhibition of cyclooxygenase-2 using a semi-homogeneous
enzymatic assay for screening of plant secondary metabolites (Huss et al. 2002). In this study
radiometric detection was employed in PKC assays [I], for studying the uptake of 45Ca2+ in clonal
rat pituitary (GH4C1) cells [II, III], and for the evaluation of monolayer integrity in Caco-2 cells by
measuring the paracellular transport of [14C]-mannitol [V].
2.5.3. Luminometric detection
Detection techniques based on luminescence are well established and widely used in bioanalytical
applications. These techniques are especially suitable for HTS because they allow rapid and
sensitive detection of analytes and can be applied to small-volume samples (Roda et al. 2003).
Luminescence can be categorised into three main types: 1) bioluminescence (biologically driven
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conversion of chemical energy into light, involving photoproteins or enzymes that may be
expressed within cells), 2) chemiluminescence (conversion of chemical energy into light by
chemical reaction), and 3) electrochemiluminescence (electrochemically driven conversion of
chemical energy into light, involves electrodes in contact with light-emitting chemicals in solution).
Luminometric techniques have been employed in both biochemical and cell-based assays.
Bioluminescent and chemiluminescent enzyme activity assays are based either on the detection of
the end products of the enzymatic reaction or on the direct, real-time evaluation of the rate of the
enzyme-catalysed reaction through its coupling with a suitable luminescent system (Roda et al.
2003). Chemiluminometric detection has been used in protein kinase assays (Lehel et al. 1997) and
in the screening of acetylcholinesterase inhibitors in 384-well format (Andreani et al. 2001).
Bioluminometric assays utilising reporter genes such as luciferase (luc) and ?-galactosidase offer a
powerful tool for studying the ability of candidate drugs to interact with cellular pathways and the
activation state of a receptor and are used to a large extent in HTS laboratories (Joyeux et al. 1997,
Roda et al. 2003). Among reporter genes, the firefly luc is one of the most commonly used, and
several transcription-based assays have been developed that allow the monitoring of GPCR
activation (Naylor 1999).
The latest innovation in bioluminescent assay technologies is bioluminescence resonance energy
transfer (BRET), a phenomenon similar to FRET occurring between a light-emitting luciferase
donor and a fluorescent protein acceptor (Roda et al. 2003).
2.5.4. Photometric detection
In photometric detection the amount of light absorbed by a solution of an organic molecule (or the
transparency of a suspension of bacterial cells) is recorded to gauge the concentration of the
molecule present in the sample. This simple methodology makes photometric assays quite useful in
certain systems, but their general lack of sensitivity limits their utilisation in miniaturised formats
for HTS (González and Negulescu 1998). High concentrations of dyes and large cell populations
are needed to achieve significant absorbance changes, and the methodology is prone to interference
caused by an absorbing matrix. For this reason, in many systems photometric detection has been
replaced by more sensitive methods such as fluorescence.
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Assays based on ultraviolet/visible (UV/Vis) absorption have recently been used for
enantioselective screening of nitrilase-producing microorganisms (Banerjee et al. 2003) and for
studying the cytotoxicity of compounds using a variety of dyes including tetrazolium reagents to
evaluate the viability of cells (Slater 2001, Mannerström et al. 2002, Riss and Moravec 2004).
Photometric detection has also recently been employed in the identification of poly[adenosine
diphosphate (ADP)-ribose] polymerase inhibitors by using a nicotinamide adenine dinucleotide
(NAD)-based assay in a 96-well plate format (Brown and Marala 2002) as well as in the evaluation
of angiogenesis activity in cultured rat aorta ring (Wang et al. 2004). In the current work,
photometric detection was applied in cytotoxicity assays to measure the release of lactate
dehydrogenase (LDH) from cells [II] and the cell proliferation and metabolic activity by using dyes
such as sulphorhodamine B (SRB) [IV] and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
(MTT) [V].
2.6. Assay miniaturisation and automation
The need to screen an increasing number of compounds against a variety of therapeutic targets has
resulted in technological advances in assay automation, miniaturisation and in the sensitivity and
specificity of detection methods aiming to increase sample throughput and to decrease costs (Bosse
et al. 2000, Sundberg 2000). High-throughput, low-volume assays have been created to achieve
these goals, and today the plate formats available range from 96-well to up to 9600-well and even
higher density formats and ‘virtual wells’ (Marron and Jayawickreme 2003). Significant savings
can be achieved through miniaturisation; a cost-benefit analysis for miniaturising a protease assay
for screening a library of 100,000 compounds is presented in Table 1.
Table 1. A cost-benefit analysis for miniaturising a protease assay for screening a 100,000-member
compound library (adapted from Oldenburg et al. 2001).
Well density Well volume (µl) Fold reagent savings Total cost ($)
96-well 200 0 209,000
384-well 50 4 139,500
1536-well 1-10 20-200 56,100
6144-well 0.2-0.7 250-1000 53,650
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Assay miniaturisation is a process of establishing optimal assay conditions for the microlitre
volumes necessary for micro-scale screening in high-density plate formats (Wölcke and Ullmann
2001). Despite the savings, miniaturisation is only feasible for robust assays with high,
reproducible signals; for assays made with well densities above 1536-well formats the use of
homogeneous assays is a necessity (Boguslavsky 2004a). Miniaturising an assay normally involves
making several changes that are necessary for implementing a high-density plate format.
Frequently, miniaturisation causes loss in assay performance (e.g. lower signal, increased
variability, loss of robustness), resulting for example from increased exposure to oxygen, higher
surface-to-volume interactions, and from the increased error associated with miniaturised liquid
handling and signal detection (Taylor 2002). The use of miniaturised assay formats therefore
requires new techniques and strategies for sample handling, assay development and assay
adaptation. Automated plate and liquid handling with high accuracy are essential as well as
refinement of the techniques used for detection and data handling (Wölcke and Ullmann 2001). In
cellular assay systems, the degree of miniaturisation is usually limited due to biological variation
and cell viability.
Depending on the throughput required, automation may need to be integrated into the assay
development (Burbaum 1998, Hertzberg and Pope 2000, Elands 2001). Automation is usually
considered to mean the use of workstations, robotic sample processors, plate stacking and moving
devices, automated HTS/uHTS assay systems etc. when in fact laboratory automation has actually
begun much earlier, starting from hand-held pipettors (Elands 2001). Microplate instrumentation
can be classified into stand-alone devices (plate washers, dispensers, readers), workstations (e.g.
liquid handlers) and robotic systems (a collection of stand-alone devices and workstations
integrated into a functional environment, controlled by system management software and one or
more robot arms to perform an application) (Elands 2001).
Before assays can be transferred onto automated platforms, improvements in robustness, stability,
signal separation, and assay variability are often required (Taylor 2002). HTS requirements for
automation include throughput that is not limited by robot, flexibility (easy set-up of new assays),
and industrial-level reliability (long unattended runs, robust equipment, good support). Most
important benefits and automation drivers are listed in Table 2. In addition to primary and
secondary screening, robotics and other automated systems are currently used in various areas of
drug discovery including early-ADME and toxicity studies (Trinka and Leichfried 2001). The
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exponential growth in using cell-base assays in the pharmaceutical industry has also led to growing
interest in cell culture automation for producing the cells needed for the assays (Koppal 2003).
Table 2. Benefits and drivers for assay automation.
Benefits of automation Automation drivers
unattended operation demands for higher sample throughput
labour saving flexibility to run different assay technologies
improved throughputs
improved results (accuracy, reproducibility etc.)
increasing demand for laborious cell-based
assays
operator-independence
environmental control
personnel safety (bio-/radiochemical)
assay transfer to HTS should be fast and
simple
demands for consistent, high quality data
sample tracking and control desire to focus screening personnel on assay
development and data analysis
By employing homogeneous fluorescence-based assays and novel signal detection techniques,
miniaturisation strategies, robotics and other laboratory automation it is possible to perform
100,000 assays per day, commonly affiliated with uHTS utilised in large-scale screening
programmes in the pharmaceutical industry (Bronson et al. 2001). The implementation of uHTS
further necessitates the development of specially designed data analysis and data management
systems for scheduling of the screening devices, handling of compound data, management of
screening results and for in-process quality control (Wölcke and Ullmann 2001).
2.7. Assay quality and validation
After initial development, the suitability of the assay for screening needs to be further evaluated
and adequate validation should be performed to ensure the high quality of screening data. The shift
from high-quantity screens towards higher information content and high-quality data has placed
greater demands on the quality of assay performance. High quality in relation to an HTS assay can
in principle be defined as the ability to separate the signals for inactive and active molecules
sufficiently to allow accurate identification of hits (Sittampalam et al. 1997a, Zhang et al. 1999).
Assays for HTS not only require small sample volume, high throughput and robustness, but also
adequate sensitivity, repeatability and reproducibility (e.g. plate-to-plate and day-to-day
variations), and accuracy in order to be suitable for automated liquid handling and signal detection
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systems. Additionally, in most HTS programmes each compound is tested only singly or in
duplicate, and high-quality data from the assay is therefore critical (Zhang et al. 1999). Equally, the
assay signal should be able to avoid perturbation by the numerous non-specific effects that can
originate from the assay components. Among the key assay interference factors are inner-filter
effects, autofluorescence, quenching and photo-bleaching (Comley 2003).
The quality of an HTS assay is typically evaluated using quality parameters such as signal-to-
background (S/B) and signal-to-noise (S/N) ratios and a screening window coefficient called the Z
factor. The S/B ratio simply measures the intensity difference between the signal and background,
whereas the S/N ratio also takes into account the impacts of signal and background variations. The
Z factor is an indicator of assay quality and reflects more precisely both the dynamic range of the
assay signal and the data variation associated with the signal measurements. The Z factor is the
ratio of the separation band (i.e. signal window) to the dynamic range of the assay signal, and
defines a parameter characterising the capability of hit identification for each given assay under the
defined screening conditions (Zhang et al. 1999). The Z factor is calculated from data gathered
from library samples showing no activity, whereas its more widely used modification, the Z’ factor,
is calculated using data from control samples. The following equations for the quality parameters
have been described in Bollini et al. (2002) and in Zhang et al. (1999): S/B = Xs/Xb, S/N = (Xs-
Xb)/(SDs2 + SDb2)1/2, Z’ = 1- [(3 × SDs + 3 × SDb)/½Xs-Xb½]. Xs and SDs represent the average and
standard deviation of the signal obtained from control samples exhibiting maximum signal. Xb and
SDb represent the average and standard deviation of the signal obtained from control samples
exhibiting no specific signal (i.e. background).
As a dimensionless parameter, the Z factor is appropriate for evaluating overall assay quality and
can be used in assay development and optimisation, e.g. to compare the effects of different assay
conditions. The Z’ factor is characteristic of the quality of the assay itself, without the intervention
of test compounds. Basically, the higher the value of the Z or Z’ factor of an assay, the higher the
data quality. Screening assays can be categorised according to their respective Z factors, which
enables different screening assays to be compared (Table 3).
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Table 3. A simple categorisation of screening assay quality in terms of the value of the Z factor
(Zhang et al. 1999, with modifications).
Z factor value Structure of assay Related to screening
1 SD = 0 (no variation), or the dynamic
range ???
An ideal assay
1 > Z ? 0.5 Separation band is large An excellent assay
0.5 > Z > 0 Separation band is small A double assay
0 No separation band, the sample
signal variation and control signal
variation bands touch
A “yes/no” type assay
< 0 No separation band, the sample
signal variation and control signal
variation bands overlap
Screening essentially impossible
However, particularly in cell-based assays, the system is prone to avoidable variation, which needs
to be taken into account when evaluating the assay quality. For cell-based assays, Z’ factors > 0.4
can be accepted (Falconer et al. 2002).
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3. AIMS OF THE STUDY
The process of finding high-quality drug candidates relies on robust, accurate and reproducible
screening assays for the evaluation of biological activity of compound libraries. In this context, the
overall aims of the study were to modify, develop and validate diverse methods in order to improve
and demonstrate their suitability for screening, and to perform small-scale screening in an academic
setting.
To achieve the overall aims the following investigations were conducted:
1) a set of natural compounds and their derivatives were screened against two enzymatic
protein PKC assays exploiting kinase activity and [3H]-phorbol ester binding, and the
suitability of these assays for screening was investigated [I]
2) a cell-based 45Ca2+ uptake assay was miniaturised, validated and automated and the
applicability of the assay for detecting calcium antagonistic components of crude extracts
in combination with high-performance liquid chromatography (HPLC) micro-
fractionation was studied [II, III]
3) a novel time-resolved fluorometric immunoassay was developed for the evaluation of
antichlamydial activity in order to increase the sample throughput, and the assay was
validated with antimicrobial agents in comparison with two reference methods:
immunofluorescence microscopy and real-time- PCR [IV]
4) the possibility of predicting the biomembrane interactions of compounds by membrane
affinity experiments in phospholipid vesicles compared to transport studies in Caco-2
cells was studied using a set of flavonoids and alkyl gallates [V]
5) assay quality parameters were employed, their applicability evaluated, and the impacts of
diverse assay formats, detection technologies and automation strategies on assay quality
were assessed
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4. MATERIALS AND METHODS
More detailed information on the experimental conditions can be found in the original publications
I-V.
4.1. Model compounds
4.1.1. Standard compounds
The PKC inhibitor staurosporine (Sigma-Aldrich Co., USA) was employed as the positive control
in the kinase activity assay, while phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich Co.,
USA), competing with the [3H]-phorbol ester, was used in the PKC? binding assay [I]. In 45Ca2+
uptake measurements verapamil hydrochloride (Orion Pharmaceuticals, Finland) and nimodipine
(RBI Research Biochemicals International, USA) were used as model compounds with known
calcium antagonistic activity [II, III]. Ketoprofen (ICN Biomedicals, USA) and paracetamol
(Orion Pharmaceuticals, Finland) were used as standard compounds in studying the permeability of
the test compounds in the Caco-2 cell monolayer [V]. [14C]-mannitol (Amersham Pharmacia
Biotech, UK) was used as a paracellular transport marker in the Caco-2 studies [V].
The accuracy of the time-resolved fluorometric immunoassay (TR-FIA) developed [IV] was
evaluated by determining the susceptibility of Chlamydia pneumoniae to a set of antimicrobial
agents. Erythromycin, rifampicin (Sigma-Aldrich Co., USA), doxycycline, ofloxacin, minocycline,
and ciprofloxacin (ICN Biomedicals, USA) were chosen for the study to represent agents with
potent antichlamydial activity, whereas streptomycin (Sigma-Aldrich Co., USA) and penicillin G
(Fluka Chemie, Switzerland) served as inactive model compounds. To investigate the possibility of
detecting compound cytotoxicity simultaneously with the TR-FIA, camptothecin (ICN
Biochemicals, USA) and Triton X-100 (Sigma-Aldrich Co., USA) were used as model compounds
exhibiting cytotoxic effects.
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4.1.2. Natural compounds and derivatives
A set of natural compounds and their derivatives were used as the library for the compounds
needed for the studies [I-III, V]. The compounds were used for screening against two PKC assays
[I] and for validating the miniaturised 45Ca2+ uptake assay [II, III]. Permeability experiments in the
Caco-2 cell monolayer and membrane affinity in phospholipid vesicles were conducted for a
selected group of flavonoids and alkyl gallates [V]. The classification and sources of all the natural
compounds and derivatives used in the present study are listed in Table 4. For the experiments, the
compounds were dissolved in DMSO to prepare stock solutions, which were diluted to
concentrations required for the assays [I-III, V] with the appropriate assay buffer.
Table 4. Classification and sources of the natural compounds and derivatives used in studies I-III
and V.
Compound Used in Source
Catechins and derivatives
(+)-Catechin I Sigma-Aldrich Co., USA
(+/-)-Catechin I Sigma-Aldrich Co., USA
(-)-Epicatechin I Sigma-Aldrich Co., USA
(-)-Epicatechin gallate I Extrasynthese S.A., France
(-)-Epigallocatechin I Extrasynthese S.A., France
(-)-Epigallocatechin gallate I Extrasynthese S.A., France
Procyanidin B1 I Extrasynthese S.A., France
Procyanidin B2 I Extrasynthese S.A., France
Coumarins
Daphnetin I Extrasynthese S.A., France
Imperatorin III Extrasynthese S.A., France
6-Methylcoumarin I Extrasynthese S.A., France
Scopoletin I, II Sigma-Aldrich Co., USA
Flavanones
Hesperidin I Extrasynthese S.A., France
Naringenin I, II, V Sigma-Aldrich Co., USA
Naringin I, V Extrasynthese S.A., France
Flavones
Acacetin I, II Carl Roth GmbH & Co., Germany
Apigenin I, II Fluka Chemie, Switzerland
Baicalin I Extrasynthese S.A., France
Flavone I, II, V Carl Roth GmbH & Co., Germany
Luteolin I, II, V Extrasynthese S.A., France
Vitexin I Extrasynthese S.A., France
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Table 4. Classification and sources of the natural compounds and derivatives used in studies I-III
and V. (cont.)
Compound Used in Source
Flavonols
Isorhamnetin I Extrasynthese S.A., France
Kaempferol I, II Extrasynthese S.A., France
Morin I, II, V Carl Roth GmbH & Co., Germany
Myricetin I, II Extrasynthese S.A., France
Myricitrin I Extrasynthese S.A., France
Quercetagetin I Carl Roth GmbH & Co., Germany
Quercetin I, II, V Merck & Co., Germany
Quercitrin I Carl Roth GmbH & Co., Germany
Rhamnetin I Extrasynthese S.A., France
Rutin III Merck & Co., Germany
Isoflavones
Daidzein I Extrasynthese S.A., France
Genistein I, II Extrasynthese S.A., France
Phenolic acids and derivatives
Benzoic acid I Merck & Co., Germany
Caffeic acid I Sigma-Aldrich Co., USA
Ferulic acid I Extrasynthese S.A., France
Gallic acid I Sigma-Aldrich Co., USA
Protocatechuic acid I Carl Roth GmbH & Co., Germany
Rosmarinic acid I Extrasynthese S.A., France
Sinapic acid I Fluka Chemie, Switzerland
Syringic acid I Sigma-Aldrich Co., USA
Dodecyl gallate I, II Fluka Chemie, Switzerland
Methyl gallate I, II, V Fluka Chemie, Switzerland
Octyl gallate III Extrasynthese S.A., France
I, II, V Fluka Chemie, Switzerland
Propyl gallate I, II, V Sigma-Aldrich Co., USA
4.2. Plant material and extraction
Extracts of Peucedanum palustre and Pinus sylvestris were used to demonstrate the applicability of
the combination of micro-fractionation and 45Ca2+ uptake assay in detecting calcium antagonistic
components of natural products [III]. Roots of milk parsley Peucedanum palustre (L.) Moench
belonging to the family Apiaceae (Umbelliferae) were collected in Kirkkonummi, Finland during
June and July 2000, and identified by Docent K. Fagerstedt of the Division of Plant Physiology,
University of Helsinki, Finland. Voucher specimens are deposited at the Faculty of Pharmacy,
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University of Helsinki, Finland (KN 1-3 and KN 6). Air-dried and powdered Peucedanum palustre
root material (1 g) was extracted with 3 × 10 ml of methanol-water (80:20, v/v) (sonication 10 min,
centrifugation 1500 × g, 10min). The combined supernatants were evaporated (water bath 35°C) to
a volume of about 2 ml and lyophilised to dryness. The dried extract was dissolved in a mixture of
methanol and DMSO (1:1, v/v) to yield a final concentration of 20 mg/ml.
Ground cortex of Scots pine Pinus sylvestris (L.) belonging to the family Pinaceae was obtained in
August 2000 from the company Ravintorengas (Finland). The ground cortex was produced
according to the company’s quality requirements. The material was extracted with acetone-water
(70:30, v/v) for 48 hours. The extract was lyophilised and the raw extract was further purified using
liquid-liquid extraction with n-hexane, chloroform and n-butanol, respectively. The sample was
finally collected and lyophilised to be used in this study.
4.3. Assays for protein kinase C activity [I]
The potential inhibitory effects of natural compounds and their derivatives on PKC were
investigated by exploiting kinase activity and [3H]-phorbol ester binding assays. Particular
emphasis was placed on demonstrating the suitability of these assays for screening using quality
parameters and determinations of repeatability and reproducibility.
4.3.1. Kinase activity assay
The inhibitory effects of the model compounds on the kinase activity of rat brain PKC were
measured by the incorporation of [32P] from [?-32P]-adenosine triphosphate (ATP) into a PKC-
specific substrate. The method has been described in detail by Chakravarthy et al. (1991). Aliquots
of partially purified rat brain homogenate were preincubated with model compounds or
staurosporine for 10 min at 30°C in a 96-well plate. The assay was initiated by addition of reaction
mixture to each well, and after incubation for 5 min at 30°C, the reaction was stopped by pipetting
an aliquot of the reaction mixture into a Millipore Multiscreen®-HV 96-well filtration plate
(Millipore Corp., USA) fitted with phosphocellulose membrane filters. After washing, the
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remaining radioactivity was measured by liquid scintillation counting (Microbeta® Trilux, Perkin-
Elmer Life and Analytical Sciences/Wallac Oy, Finland).
4.3.2. [3H]-phorbol ester binding assay
The ability of the test compounds to compete with [3H]-phorbol ester in binding to the regulatory
domain of PKC? (a PKC isoform) was determined according to Gopalakrishna et al. (1992). Insect
cell line derived from Spodoptera frugiperda (Sf9) expressing the human PKC? was used as the
source of PKC?. Total lysate from Sf9 cells was preincubated with the model compounds or PMA
for 10 min at room temperature in a Millipore Multiscreen®-HV 96-well filtration plate (Millipore
Corp., USA). The assay was initiated by addition of reaction mixture, and the plate was incubated
for 10 min. Proteins were precipitated with 20% polyethyleneglycol and after 15 min incubation
the filters were washed and the plates were dried. Inhibition of [3H]-phorbol ester binding was
determined by measuring the sample-associated radioactivity by liquid scintillation counting
(Microbeta® Trilux, Perkin-Elmer Life and Analytical Sciences/Wallac Oy, Finland).
4.4. Miniaturised 45Ca2+ uptake assay [II, III]
Depolarisation-induced 45Ca2+ uptake assay in clonal rat pituitary cell line GH4C1, previously used
on the Petri dish scale to measure the calcium channel modulating effects of compounds such as
flavonoids (Törnquist and Tashjian 1989, Summanen et al. 2001), was miniaturised into a 96-well
plate format. Cell seeding density (range 2 × 104 to 1 × 105 cells/well) and culture time (from 1 to 7
days) were optimised by following cell proliferation using protein determination according to
Bradford (1976). After optimisation, cells were seeded at a density of 8 × 104 cells/well, cultured in
the plates for 3 days before the experiments, refed once and assayed following the procedure of
Törnquist and Tashjian (1989) as shown in Fig. 4. Cell-associated radioactivity was measured
using a liquid scintillation counter (Microbeta® Trilux, Perkin-Elmer Life and Analytical
Sciences/Wallac Oy, Finland). The validity of the miniaturised assay was checked by measuring
the inhibitory effects of known calcium antagonists (verapamil and nimodipine) and a set of natural
compounds comprising mainly flavonoids. The suitability of the assay for automation was
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evaluated by conducting a series of experiments on a Biomek FX workstation (Beckman Coulter,
Inc., USA).
Figure 4. The protocol for performing the 45Ca2+ uptake assay in clonal rat pituitary cell line
GH4C1 in 96-well format.
4.4.1. Coupling of miniaturised 45Ca2+ uptake assay with HPLC micro-fractionation [III]
The miniaturised 45Ca2+ uptake assay was coupled to HPLC micro-fractionation of a reference
solution (containing imperatorin, octyl gallate, rutin and verapamil) and crude plant extracts. The
HPLC separations were carried out using a Discovery® HS C18 column (25 cm x 4.6 mm i.d., 5
mm, Supelco, USA) on a Perkin-Elmer Series 200 LC pump and autosampler (USA) with a 200 ml
sample loop, Perkin-Elmer LC 235 C Diode Array Detector (USA) at wavelengths of 255 nm and
320 nm and a PE Nelson 600 series link (USA). The mobile phase consisted of methanol and 0.1%
(v/v) aqueous formic acid at a flow rate of 1 ml/min. A linear gradient (from 5 to 95% methanol -
0.1% (v/v) aqueous formic acid) of 15 and 20 min followed by a 10-min isocratic period were used
for the reference solution and for the plant extracts, respectively. Micro-fractionation of the
samples was performed with an automated fraction collector (Gilson FC 204, USA) connected to
the HPLC system. The fractions were collected in 96-well microplates with a well volume of 330
ml. Fractionation was performed as a function of time, with a collection time of 0.3 minutes per
well. Fractionated samples were lyophilised for 24 hours, dissolved in assay buffer, and the
calcium antagonistic activity of the fractions was measured with the 45Ca2+ uptake assay.
GH4C1 cells
10 min 15 min Shaking10 min
Test compound/vehicle,
45Ca2+ and K+
Washing × 3,
Addition of scintillator
Scintillation countingBuffer
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4.5. Assays for susceptibility testing of C. pneumoniae [IV]
4.5.1. Cell culture and infection of cells with C. pneumoniae
Cells originating from the human respiratory tract (HL) were used as host cells for the propagation
of C. pneumoniae Kajaani 7 and for the susceptibility experiments. The cells were seeded in 96-
well plates in the TR-FIA experiments and in 24-well plates in the immunofluorescence (IF)
microscopy and real-time PCR experiments. Confluent cell monolayers were inoculated with C.
pneumoniae elementary bodies (EB) by centrifugation (550 × g, 60 min) and after 72 h incubation
the infection rate of the cultures was determined by TR-FIA, IF microscopy or real-time PCR.
4.5.2. Time-resolved fluorometric immunoassay (TR-FIA)
To increase the throughput in susceptibility testing of chlamydia, a time-resolved fluorometric
immunoassay was developed and validated. In the TR-FIA chlamydial inclusions in 96-well plates
are stained with a genus-specific murine monoclonal antibody (Anti-Chlamydia genus no. 11-113,
clone 5, Argene S.A., France) labelled with isothiocyanate-activated europium (Eu)-DTTA chelate
at Wallac Oy (Finland). The C. pneumoniae inoculum concentration and labelling conditions (incl.
label concentration, incubation time and temperature) were optimised using quality parameters to
evaluate the assay performance. In the optimised TR-FIA the inclusions were labelled with 100 µl
of the TR-FIA antibody (conc. 100 ng/ml), incubated for 30 min at 37°C and washed six times with
300 µl of Wallac DELFIAÒ Wash Solution (Perkin-Elmer Life and Analytical Sciences/Wallac Oy,
Finland) using a Biohit BW50 plate-washer (Biohit Plc, Finland). An aliquot of 100 µl of
DELFIAÒ Enhancement Solution (Perkin-Elmer Life and Analytical Sciences/Wallac Oy) was
added and the plate shaken for 5 min at low mode on a DELFIAÒ Plateshake (Perkin-Elmer Life
and Analytical Sciences/Wallac Oy). Chlamydia-associated TRF signals were measured using a
protocol optimised for europium in a Victor2 multilabel counter (excitation/emission 340/615 nm,
counting delay and window 400 µs, counting cycle 1000 µs) (Perkin-Elmer Life and Analytical
Sciences/Wallac Oy). A schematic illustration of the TR-FIA protocol is presented in Fig. 5. The
reliability of the assay was further confirmed by determining the susceptibilities of C. pneumoniae
reference strain Kajaani 7 to a set of antimicrobials by the TR-FIA and by two reference methods,
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IF microscopy and real-time PCR. The possibility of determining the cytotoxic effects of test
compounds simultaneously with the TR-FIA was assessed by incorporating a protein dye SRB
(Molecular Probes Inc., USA) into the TR-FIA labelling solution at a concentration of 0.8% (w/v).
Absorbance at 550 nm was used to calculate loss of cells from treated wells as compared with
untreated controls to evaluate the possible cytotoxicity of the samples (see also chapter 4.7).
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Figure 5. Schematic illustration of the TR-FIA protocol.
4.5.3. Immunofluorescence (IF) microscopy
For IF staining the HL cells were infected on cover slips and the chlamydial inclusions labelled
with genus-specific fluorescein isothiocyanate-conjugated monoclonal antibody (PathFinderÒ
Chlamydia Culture Confirmation System, Bio-Rad S.A., USA). The chlamydial inclusions shown
as green fluorescence were examined using a fluorescence microscope with an excitation filter
bandwidth of 510-560 nm and a 590 nm barrier filter (Nikon ECLIPSE TE300 inverted microscope
with TE-FM epi-fluorescence attachment, Japan). Inclusions in four randomly chosen fields
(magnification × 200) were counted from duplicate samples in each minimum inhibitory
concentration (MIC) determination.
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4.5.4. Real-time PCR
DNA from infected cells was extracted using a Qiagen DNA mini-kit (Qiagen Inc., USA). Real-
time PCR was used to measure the C. pneumoniae DNA present in the samples using the FastStart
DNA Master SYBR Green I kit (Roche Biochemicals, Germany), VD-4 primers (Tib molbiol,
Germany) and the conditions described by Tondella et al. (2002). Amplification and detection of
the PCR product were performed with a standard procedure of a LightCycler instrument (Roche
Biochemicals) using the following thermal cycling conditions: 50°C for 2 min, 95°C for 10 min,
and 40 cycles of 95°C for 15 s and 60°C for 1 min. The PCR product was detected as an increase in
fluorescence of the SYBR Green dye after the PCR extension phase as a result of binding to newly
synthesised double-stranded DNA. The amount of fluorescence is proportional to the amount of
DNA, and by measuring the fluorescence after each cycle the increase in DNA concentration in the
samples can be monitored in real time.
4.6. Assays for biomembrane interactions [V]
4.6.1. Permeability studies in Caco-2 cell monolayers
The human colon adenocarcinoma cell line Caco-2 [American Type Culture Collection (ATCC) #
HTB-37] was used to evaluate the transport of flavonoids and alkyl gallates across a cell
monolayer. For the experiments, the cells were cultured on polycarbonate membranes for 21-27
days. During differentiation, Caco-2 cells form a monolayer with well-distinguishable apical and
basolateral membranes, and can be used as an in vitro model of the intestinal barrier. A schematic
illustration of the principal drug transport mechanisms across the intestinal epithelium is presented
in Fig. 6. In this study, the apical-to-basolateral transport of a set of flavonoids and alkyl gallates
was investigated with Caco-2 cell monolayers. During the course of this study, the assay format
was miniaturised from 12-well to 24-well plates. After washing with physiological Hanks’
balanced salt solution (HBSS), the test compounds were added in buffer to the apical compartment
and samples from the apical and basolateral compartments were collected at several time points to
measure the transport. The samples were analysed by reversed phase HPLC using octadecyl silica
stationary phases. For samples containing flavonoids and alkyl gallates a gradient elution (from 5
to 95% methanol - 0.1% aqueous formic acid) of 10 min followed by a 10-min isocratic section
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with diode array detection at a wavelength of 255 nm was used. Ketoprofen and paracetamol
samples were analysed by isocratic elution with mobile phases consisting of acetonitrile - 0.03%
phosphoric acid (50:50, v/v) or water-methanol-acetic acid (65:35:0.4, v/v), respectively, and
detected with an absorbance detector at a wavelength of 254 nm (ketoprofen) or 245 nm
(paracetamol).
Based on the HPLC results, the apparent permeability coefficients, Papp (cm/s) across the cell
monolayers were calculated, if transport was detected, according to the equation Papp = (DQ/Dt)/(60
× A ´ Co), where DQ/Dt is the flux of the compound across the monolayer, 60 the conversion from
minutes to seconds, A (cm2) the surface area of the insert, and Co the initial compound
concentration in the apical compartment. Monolayer integrity was assessed during the experiments
by transepithelial electrical resistance (TEER) measurements and by [14C]-mannitol permeation
across the cell monolayer.
A B C D E
Figure 6. Schematic presentation of intestinal epithelium and principal drug transport mechanisms:
(A) passive transcellular diffusion, (B) passive paracellular diffusion, (C) active transport, (D)
efflux, and (E) endocytosis (adapted from Artursson et al. 1996 and Lindmark 1997).
4.6.2. Membrane affinity experiments
The work was carried out at the Department of Biochemistry and Pharmacy (Åbo Akademi
University, Turku, Finland). Membrane affinity experiments using bilayer model membranes
comprising 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC) as the bilayer-forming
43
phospholipids were used to study association of the model compounds with the membranes.
Methods based on fluorescence quenching were employed to determine the partition coefficients
(given as Kd). The method was originally based on procedures previously described by Verkman
(1980) and van Dijk et al. (2000). Kd values were obtained by gradual addition of model
compounds into vesicles with the fluorescent probe diphenylhexatriene (used for flavones and
flavonols) or p-terphenyl (used for naringenin, ketoprofen and paracetamol).
4.7. Cytotoxicity assays [II, IV, V]
In this study, the cytotoxicity of the model compounds was determined prior to the experiments to
eliminate the possibility of false positives caused by compound cytotoxicity. The assays used were:
1) LDH assay described by Korzeniewski and Callewaert (1983) [II], 2) SRB assay used for the
assessment of drug-induced cytotoxicity through measurement of the protein content of cells
(Skehan et al. 1990) [IV], and 3) MTT assay measuring the metabolic activity of the cells
according to Mosmann (1983) [V].
4.8. Data analysis
After screening at a single concentration, dose-response analyses were performed for compounds
showing potent activity [I, II]. The concentrations yielding 50% inhibition (IC50) were determined
by fitting the data into four parameter logistic curves using SigmaPlot 2002 for Windows Version
8.0 software (SPSS Inc., USA). The susceptibility results in [IV] were reported as MIC values, i.e.
the lowest concentration of the antimicrobial agent at which the chlamydia infection was inhibited.
The repeatability and reproducibility of the assays [I, II, IV] were evaluated by determining plate-
to-plate and day-to-day variations in the results obtained for positive controls. The suitability for
screening was further assessed by calculating quality parameters S/N and S/B ratios and Z’ factors
according to the equations described in Bollini et al. (2002) and in Zhang et al. (1999) (see chapter
2.7). The optimisation and validation data were used to set case-specific thresholds for the
parameters to be used in future experiments for the evaluation of data quality [I, II].
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5. RESULTS
The main results obtained during the course of this study are summarised in the following section.
5.1. Screening of protein kinase C inhibition and binding [I]
A group of natural compounds and their derivatives (43 compounds in total) were screened in this
study to evaluate their inhibitory effects on PKC with two enzymatic assays based on 1) measuring
the kinase activity of partially purified rat brain extract and 2) measuring the binding of [3H]-
phorbol ester to recombinant human PKC?.
Inhibition of protein kinase C activity. The inhibition of kinase activity was studied by measuring
the ability of PKC to incorporate [32P] from [?-32P]-ATP into a PKC-specific substrate in the
presence of the test compound. Nine compounds out of the 43 examined exhibited significant
inhibition of PKC activity. The most potent inhibitors were the catechins (-)-epigallocatechin
gallate and (-)-epicatechin gallate which had IC50 values of 4.8 and 5.9 µM, respectively. Five
flavonols (myricetin, quercetin, rhamnetin, isorhamnetin and kaempferol) and one flavone
(luteolin) also showed potent inhibition, the IC50 values ranging from 7.8 to 33.7 µM (Table 5).
Table 5. Inhibition of protein kinase C activity by the most potent inhibitors given as
concentrations resulting in 50% inhibition (IC50) in the kinase activity of partially purified rat brain
extract.
Compound IC50 (µM)
Dodecyl gallate 8.9
(-)-Epicatechin gallate 5.9
(-)-Epigallocatechin gallate 4.8
Isorhamnetin 26.5
Kaempferol 33.7
Luteolin 15.5
Myricetin 7.8
Quercetin 13.5
Rhamnetin 14.4
Staurosporine (positive control) 0.003
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The gallic acid derivative dodecyl gallate was also found to be a good inhibitor of PKC (IC50 of 8.9
µM), while the derivatives with shorter side chains, e.g. methyl and propyl gallate, caused only
modest or negligible inhibition. Insignificant effects were noted for coumarins, flavanones,
isoflavones and simple phenolic acids [I, Fig. 1].
Inhibition of phorbol ester binding. Phorbol ester binds to the regulatory domain of PKC causing
activation. Most of the diversity between different PKC isoforms is in the regulatory domain
(Mellor and Parker 1998) and the binding to this site could be an indication of isoform selectivity.
None of the compounds used in this study competed effectively with the binding of [3H]-phorbol
ester to the regulatory domain of PKC? [I, Table 1]. The most potent were (-)-epigallocatechin
gallate, rhamnetin, (-)-epicatechin gallate and dodecyl gallate, which produced inhibitions of 59%,
49%, 45%, and 40%, respectively, at a concentration of 150 µM. These results would indicate that
the PKC inhibition seen in the kinase activity assay was mainly due to binding to the catalytic
domain of PKC.
Assay quality and performance. The second specific aim of the study [I] was to evaluate quality
parameters for the two assays, i.e. how well they are suited for screening. Reproducibility was
assessed on the basis of results relating to positive controls, which were staurosporine for the
kinase activity assay and PMA for the [3H]-phorbol ester binding assay. Plate-to-plate and day-to-
day variations in the kinase activity were 3.3% (n = 3 in duplicate) and 10.1% (n = 10), and for the
[3H]-phorbol ester binding assay 0.5% (n = 3 in duplicate) and 3.7% (n = 4), respectively. Assay
quality parameters S/B, S/N and Z’ factor were 16.1, 11.3, and 0.62 (n = 14) for the kinase activity
assay and 47.4, 15.9 and 0.73 (n = 10) for the [3H]-phorbol ester binding assay, respectively. These
figures indicate that both assays are sensitive, reproducible, and able reliably to detect PKC
inhibition. Z’ factor values above 0.5 show the suitability of the assays for screening.
5.2. Assay development for screening of calcium channel blocking activity [II,
III]
The clonal rat pituitary cell line GH4C1 possesses a high concentration of L- type voltage-operated
calcium channels (VOCCs) similar to those found in cardiovascular tissue (Tan and Tashjian 1984,
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Wagner et al. 1993). The VOCCs mediate a variety of biological processes in the cardiovascular,
central nervous system (CNS) and metabolic areas, making these channels a highly important,
physiologically relevant target for screening of inhibitors (Denyer et al. 1998). The GH4C1 cell line
has been extensively used on the Petri dish scale for studying the calcium antagonistic properties of
compounds and natural products (Rauha et al. 1999, Haansuu et al. 1999, Haansuu et al. 2001,
Summanen et al. 2001). However, the method previously employed is very laborious and has a low
throughput.
Assay miniaturisation. The assay for studying calcium uptake in GH4C1 cells was miniaturised into
96-well plate format and the assay conditions relating to cell culture were optimised [II]. Cell
proliferation in the 96-well plate was assessed by using the protein content of the wells as a
measure of cellular growth. Wells were seeded with starting cell densities ranging from 2× 104 to 1
× 105 cells/well, and cellular growth was followed for 7 days by protein determination. Cellular
growth reached the same plateau level of approx. 3 × 105 cells/well after 3 days when 8 × 104 and 1
× 105 cells were seeded per well, and after 4 days with a starting density of 6 × 104 cells/well [II,
Fig. 1; erroneously 105]. As a result, the incubation time prior to experiments could be reduced
from 7 to 3 days. The seeding density 8 × 104 was found to be the optimum. The edge-wells were
omitted from the experiment due to variable cellular behaviour in these wells seen as increased data
variation.
Assay validation and performance. The reliability of the assay in measuring calcium channel
activity was evaluated using the calcium antagonists verapamil and nimodipine together with a set
of natural compounds and their derivatives (15 compounds in total) as model compounds. IC50
values for nimodipine and verapamil obtained with the miniaturised assay were 0.007 and 3.4 µM,
respectively. Four compounds inhibiting the 45Ca2+ flux were identified from amongst the natural
compounds and derivatives: octyl gallate, naringenin, flavone and genistein. The most potent of
these compounds was octyl gallate, with an IC50 of 34 µM [II, Table 2].
The majority of the compounds were observed to be calcium channel activators, the most effective
being myricetin (99% increase in 45Ca 2+ entry, Fig. 7) [II, Table 3]. Myricetin was also able to
increase the 45Ca2+ flux by 42% when the experiment was performed without K+ depolarisation,
whereas the more moderate activators, i.e. apigenin, kaempferol and dodecyl gallate, had no effect
on the 45Ca2+ flux without K+ stimulation. The assay can easily be modified to study the mechanism
47
of activation in more detail, e.g. by the addition of H-89, a cyclic 3’,5’-adenosine monophosphate
(cAMP)-dependent protein kinase A (PKA)-inhibitor, to influence the upmodulation of VOCCs by
cAMP-dependent PKA. Of the activators, myricetin and dodecyl gallate were able to induce an
increase in the 45Ca2+ uptake under H-89 suppression, which suggests that they act through a
cAMP-independent pathway.
In summary, the results obtained agreed well with our previous data (Härmälä et al. 1992, Haansuu
et al. 2001, Summanen et al. 2001) demonstrating the ability of the miniaturised assay to yield
reliable information on the calcium channel modulating effects of compounds.
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Figure 7. The effects of the model compounds (at a concentration of 50 µM) on 45 Ca 2+ uptake in
GH4C1 cells determined with the 96-well plate assay (the bars show the mean ± S.E.M. from two to
four separate experiments, each with six replicates).
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The suitability for screening was evaluated on the basis of quality parameters and data repeatability
and reproducibility. The S/B and S/N ratios averaged 3.9 and 10.3, respectively, and the Z’ factor
0.59 (n = 9) in the series of experiments performed with the model compounds. Verapamil was
used as a positive control during the course of this study, and was included at a concentration of 40
µM (yielding an average inhibition of 88%) on every assay plate and employed in assessing the
repeatability and reproducibility of the results. The plate-to-plate and day-to-day variability in the
results obtained for verapamil were 4.2 (n = 3 in triplicate) and 5.0% (n = 5), respectively.
Assay automation. The suitability of the cell-based 45Ca2+ uptake assay for automation was
evaluated by running a series of experiments on a Biomek FX workstation. Markedly lower values
for the quality parameters and higher variability of results were observed in the automated
compared with the manual experiments (Fig. 8). The S/B, S/N, and Z’ factors were 2.6, 5.3, and
0.22 (n = 5), respectively, for the automated version of the assay. However, this did not have a
significant effect on the IC50 values obtained for the calcium channel inhibitors. From the
automated experiments the IC50 values for verapamil and nimodipine were 3.7 and 0.010 µM,
respectively, whereas the manual experiments yielded values of 3.4 and 0.007 µM.
Figure 8. Dose-response curves for verapamil and nimodipine determined by (A) manual and (B)
automated 45Ca2+ uptake assay in GH4C1 cells. Data points represent the mean ± standard deviation
of six replicates.
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Coupling of miniaturised 45Ca2+ uptake assay to HPLC micro-fractionation. The automated,
miniaturised 45Ca2+ uptake assay in GH4C1 cells was successfully coupled to HPLC micro-
fractionation of plant extracts [III]. With a reference solution containing verapamil, octyl gallate,
imperatorin and rutin, the accuracy of the integrated assay in detecting calcium channel antagonists
and the effects of micro-fractionation and lyophilisation were assessed. The theoretical final
concentration of the compounds was calculated to be 16 µg/ml in the 45Ca2+ uptake assay. These
concentrations yielded inhibitions of 100, 93, and 79 for verapamil, imperatorin, octyl gallate,
respectively, when the effects of these compounds on the 45Ca2+ uptake were measured without a
prior HPLC micro-fractionation step. No effect was observed with rutin. For the micro-fractionated
reference solution, the following inhibitory effects were detected: verapamil 34-79% (fractionated
into 5 wells), imperatorin 6-42% (fractionated into 3 wells), octyl gallate 11-49% (fractionated into
2 wells), and rutin showed no effect [III, Fig. 1]. Clearly, these results indicate that the HPLC
micro-fractionation did not cause any significant loss of activity in the model compounds, although
direct comparison of results between unfractionated and fractionated samples was not possible due
to the fractionation of one compound into several wells on the plate. Based on the experiments
made with the reference solution, the threshold for considering a substance active was set at 30%.
To further show the suitability of the assay for diverse types of samples, primary detection of
calcium antagonistic components from plant extracts was performed. This would also be beneficial
when working with other complex mixtures such as synthetic mixtures and fermentation broths. A
root extract of Peucedanum palustre causing a total inhibition of 45Ca2+ flux, and Pinus sylvestris
extract showing no activity were chosen as model extracts for the experiments. The HPLC micro-
fractionation of the extracts was performed, the fractions were lyophilised, dissolved in assay
buffer and subjected to the 45Ca2+ uptake assay. HPLC chromatograms were combined with activity
profiles enabling us to detect the active components direct from the chromatogram [III, Fig. 2].
The calcium channel blocking activity of P. palustre root extract could be linked to components
identified by HPLC-UV, LC-MS and retention time as isoimperatorin and columbianadin.
Columbianadin has previously been reported to be the most active calcium channel inhibiting
compound in the root extract of P. palustre (Vuorela 1988). As anticipated, no significantly
inhibitory components were detected from the P. sylvestris extract (inhibitions under 18%) [III,
Fig. 3].
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5.3. Assay development for screening of antichlamydial activity [IV]
A novel time-resolved fluorometric immunoassay (TR-FIA) was created to increase the sample
throughput in the screening of antichlamydial activity. The assay is based on a europium-
conjugated, genus-specific antibody, which allows a multilabel counter to be used for measuring
the presence of chlamydial inclusions in the samples. By employing time-resolved fluorometry as
the detection technology, the interfering autofluorescence from the host cells could be eliminated
through temporal resolution.
Assay development and optimisation. The assay was miniaturised from the previous 24-well plate
format to a 96-well plate format in which the seeding of 6 × 104 HL cells/well was shown to result
in confluent monolayers when grown overnight prior to infection. On the basis of experiments with
a series of C. pneumoniae inoculum concentrations ranging from 0.26 × 103 to 26 × 106 inclusion-
forming units (IFU)/ml, the cells were infected in the optimised TR-FIA protocol with an inoculum
of 4 × 105 IFU/ml. This yielded excellent values for the quality parameters (S/B = 5.07, S/N = 9.27,
Z’ = 0.66) and a reliably high infection rate as visually determined by IF staining experiments. The
TR-FIA was able to detect an inoculum of 2.6 × 103 IFU/ml, corresponding to 90 IFU/well, but the
concentration should be greater than 26 × 103 IFU/ml before reliable difference between infected
and non-infected cells can be obtained if evaluated by the signal and the quality parameters [IV,
Fig. 1, Table 2]. With the aim of improving the assay performance, optimal labelling conditions as
regards label concentration, incubation time and temperature were determined by calculating the
quality parameters from the data obtained for each set of conditions [IV, Fig. 1, Table 1]. From the
results, a concentration of 100 ng/ml and an incubation of 30 min at 37°C were selected. With these
conditions, the quality parameters were: S/B 6.84, S/N 6.69 and Z’ 0.52.
Assay quality and performance. The TR-FIA showed excellent repeatability and reproducibility
for a cell-based assay. Using erythromycin (7.8 ng/ml) as a positive control, plate-to-plate variation
was 8.9% (n = 3) and day-to-day variation 9.0% (n = 3). Variation in the infection rate within one
plate was investigated by infecting all 96 wells of one plate. When all the wells were included, the
variation in the measured signal corresponding to the infection rate was 18%, but this was reduced
to 12% when the edge-wells were excluded (signals measured from individual wells are presented
in Fig. 9). Apparently, the 3-day incubation during the infection caused significant evaporation in
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the edge-wells and led to divergent results for the infection rate. For this reason the edge-wells
were not used in the subsequent experiments.
Data on the quality parameters was collected during the validation experiments. The average S/B
and S/N ratios were 6.48 and 6.85, respectively, and the Z’ factor 0.39 (n = 19). Although not ideal,
these values can be regarded as good for a cell-based assay in which there is a second source of
biological variation, i.e. chlamydia. The assay is thus suitable for screening but the quality
parameters should be carefully examined after each experiment to detect any problems with the
experimental outcome, i.e. the success of infection.
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Figure 9. Within-plate variability of the maximum signal in the TR-FIA. The 3D surface graph has
been constructed from signals measured from individual wells of one 96-well plate. The signals
have been categorised and the levels are presented with different colours in the graph, dark colours
representing high and light colours low signal levels. The numbers and letters on the X and Z axes
represent the column and row titles on the plate, respectively.
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Assay validation. The susceptibility (measured as MICs) of C. pneumoniae Kajaani 7 to a set of
antimicrobial agents was determined using the TR-FIA, IF microscopy and real-time PCR to show
the reliability of the TR-FIA. In summary, MICs determined using the three methods agreed well,
with TR-FIA and IF microscopy yielding almost identical results [IV, Table 3]. Real-time PCR
seemed to give slightly lower MIC values than the other two methods, but the differences were
generally only one dilution lower and thus insignificant. The three most potent agents in inhibiting
chlamydial infection were rifampicin, erythromycin and doxycycline, with MIC values of 0.008
(0.004 according to PCR), 0.016 and 0.063 µg/ml, respectively. The quinolones ciprofloxacin and
ofloxacin inhibited infection, with MIC values of 0.5-1.0 µg/ml, and a MIC of 0.063 µg/ml (0.031
µg/ml for PCR) was obtained for minocycline. Penicillin G and streptomycin were found to be
inactive. The former showed no inhibition at concentrations up to 72 µg/ml according to TR-FIA
and IF staining, whereas the MIC was 18 µg/ml according to PCR. No activity was observed with
streptomycin at concentrations of 288 µg/ml (72 µg/ml for PCR).
Simultaneous cytotoxicity assessment. Cytotoxicity of the test compounds can result in false
positives, and should therefore be evaluated in cell-based screens. The best way to perform the
cytotoxicity assessment would be to combine it with the actual bioassay. In the TR-FIA the
addition of SRB to the TR-FIA antibody solution enabled the concomitant cytotoxicity assay. SRB
is a dye which can be used to evaluate the loss of cells caused by test compound treatment. Despite
some interference between the TR-FIA antibody and SRB, the assay was shown to be reliable when
dual labelling with the SRB was performed (S/B = 3.18, S/N = 5.55, Z’ = 0.35). The cytotoxicity of
camptothecin and Triton X-100 causing overestimation of chlamydial susceptibility was clearly
detectable with the dual labelling assay [IV, Fig. 2].
5.4. Comparison of membrane interactions in Caco-2 cells and in
phospholipid vesicles [V]
The biomembrane interactions of a set of flavonoids and alkyl gallates (11 in total) were examined
using transport studies on Caco-2 cells and membrane affinity experiments in phospholipid
vesicles. The degree of hydroxylation, molecular configuration, and length of the side chain were
found to markedly influence the membrane partition and permeability characteristics of these
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compounds. Flavonoids with no or up to three free hydroxyl groups were transported across the
Caco-2 cell monolayer, i.e. flavone and naringenin with Papp values of 380 × 10-6 and 29.4 × 10-6
cm/s [V, Table 1], respectively, whereas flavonoids with several hydroxyl groups, e.g. quercetin
and luteolin, were rapidly taken up by the cells but not transported to the basolateral compartment
[V, Fig. 2]. The apical concentration of catechin isomers (+)-catechin and (-)-epicatechin was not
reduced during the 90-min incubation and were thus unable to penetrate the cell membrane.
Polyhydroxylated flavonoids exhibited the highest affinity for POPC vesicles, the partition
coefficients (Kd) being 7.1 and 7.5 µM for luteolin and quercetin, respectively. On the other hand,
the membrane affinity of flavone was weak (Kd = 115 µM). In conclusion, high membrane affinity
seemed to result in poor transepithelial transport of the compound. The degree of hydroxylation
and molecular configuration were seen to be critical factors in membrane affinity and the
transcellular transport of flavonoids.
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6. DISCUSSION
6.1. Relevance of the targets
The assays employed in this study were targeted at the evaluation of protein kinase C (PKC)
activity [I], 45Ca2+ uptake via voltage-gated calcium channels (VOCCs) [II, III], the susceptibility
of Chlamydia pneumoniae [IV] and biomembrane interactions [V].
The family of PKC isozymes are important signal transducers in a number of cellular responses
including cell proliferation and tumorigenesis and have been connected with various pathological
disorders including cancer, heart disease and diabetes (Newton 1997). PKC?, one of the PKC
isoforms, has been reported to suppress apoptosis in several cell lines (Dean et al. 1996, Connolly
and Rose 1997, Gutcher et al. 2003). It has also been predicted that PKCs will be major drug
targets in the twenty-first century (Cohen 2002). Selective PKC inhibitors have been described for
the treatment of diabetic retinopathy (Engel et al. 2000, Cohen 2002).
Voltage-operated calcium channels are found in cardiac, neuronal and skeletal tissues and have a
crucial role in the regulation of excitation-contraction coupling in smooth muscle (Tsien and Tsien
1990, Denyer et al. 1998). Calcium channel inhibitors are used in treating angina, arrhythmia,
hypertension, migraine, and atherosclerosis (Denyer et al. 1998). Indeed, 15% of the 100 top-
selling drugs worldwide are ion channel modulators (England 1999). The clonal rat pituitary cell
line, GH4C1, used in this study [II, III], possesses a high concentration of L-type VOCCs (Tan and
Tashjian 1984). Depolarisation-induced 45Ca2+ uptake through voltage-gated calcium channels has
been well characterised in GH4C1 cells (Tan and Tashjian 1984) and treatment with known calcium
channel blockers causes a high inhibition of the Ca2+ flux, making this cell line an excellent model
for studying the calcium channel modulating effects of compounds.
C. pneumoniae is an obligate intracellular bacterium causing acute infections such as pharyngitis,
bronchitis and pneumonia as well as chronic infections associated with various diseases, including
atherosclerosis (Saikku et al. 1988, Grayston et al. 1995), asthma (Hahn et al. 1991, Hahn et al.
1996) and CNS symptoms (Koskiniemi et al. 1996). No specific treatment for C. pneumoniae
infections exists and chronic infections have been found to be extremely difficult to diagnose and
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treat with current antimicrobial agents. Screening for new potential antichlamydial agents has
therefore unquestionable importance, but has been hampered by the lack of a high-throughput assay
for C. pneumoniae susceptibility testing. Development of the novel TR-FIA [IV], the first higher
throughput method for screening antichlamydial activity, greatly benefits the methodology and
speeds up the screening process.
Biomembrane interactions and cellular membrane permeability are of pivotal importance to the
activity of the compounds employed in cell-based assays as well as for their bioavailability (Seydel
2002). Oral absorption characteristics are usually estimated in vitro using differentiated monolayer
cultures of human colon adenocarcinoma cell line Caco-2 to mimic the monolayer of intestinal
epithelial cells lining the gastrointestinal tract (Artursson and Karlsson 1991, Artursson et al.
1996). Due to the laboriousness of this method, several other techniques have been investigated as
possible alternatives, including parallel artificial membrane permeation assay (PAMPA), surface
plasmon resonance biosensor technique, the use of immobilised artificial membrane (IAM)
columns, and partitioning into immobilised liposomes (Seydel 2002, Di and Kerns 2003). In the
present study, the Caco-2 model and a biochemical assay measuring the partitioning into
phospholipid vesicles were used to study a group of flavonoids and alkyl gallates to compare the
functionality of these methods in predicting the biomembrane interactions of these compounds [V].
6.2. Biochemical versus cell-based assays
An assay for bioactivity screening can be based on examining either isolated targets such as
purified enzymes or proteins or targets in a cellular environment. The two PKC assays utilised in
this study were based on a mixture of enzymes extracted from rat brain and on a recombinant
PKC? expressed in baculovirus-infected insect cells [I]. The membrane affinity experiments were
conducted using POPC vesicles [V]. In the three cell-based assays, cell lines GH4C1 [II, III], HL
[IV] and Caco-2 [V] were employed.
The benefits of the biochemical assays are quite clearly seen in this study: they show excellent
reproducibility and performance in terms of quality parameters and are significantly faster to
perform (e.g. no cell culture time is needed prior to experiments). On the other hand, the
knowledge obtained is quite limited; potent inhibitors could be recognised but this does not yet
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give any indications as to whether these compounds will ultimately function in a cellular
environment. In fact, the two most prominent PKC inhibitors identified [I] were catechin
derivatives, and for similar compounds both cellular uptake and permeability in Caco-2
experiments were shown to be very slow [V], which should raise some concerns over their
functionality.
Direct information on the ability of compounds to affect cellular targets such as VOCCs [II, III] or
on their cytotoxicity [II, IV, V] can be achieved using cell-based assays for screening. More
complicated assay systems are usually needed, which places additional requirements on assay
design, development and optimisation. During experiments, cells may change their biological
properties and response due to any experimental variability, such as temperature, pH, media, serum
concentration or cell density, so that particularly careful planning of procedures is a necessity for
cell-based assays (Boguslavsky 2004b). As shown by the optimisation of the cell culture procedure
for the 45Ca2+ uptake in GH4C1 cells [II], the determination of optimal cell seeding density and
growth phase of the cells can have a significant effect on the cell culture needs for screening. The
high within-plate variation and edge-effects in signal noted with the two 96-well format cellular
assays developed in this study [II, IV] is a result of variations in cell growth across the assay plate
during long incubations, probably caused by temperature variations or media evaporation.
Compound cytotoxicity can lead to false positives, and should thus always be examined in cellular
assays. The best approach would be the simultaneous determination of cytotoxicity and the actual
biological activity to be evaluated, such as the coupling of a cell proliferation assay to antibody
labelling [IV].
Cell-based assays are also irreplaceable in situations where the specific target for pharmacological
intervention has not been recognised, which is the case in infections caused by chlamydia [IV]. On
the other hand, one of the disadvantages of using cell-based screens is that it is hard to determine
the exact mechanism of compound activity (Oldenburg et al. 2001).
The ability of compounds to interact with biomembranes, i.e. their cellular permeability, is of great
importance during the screening process. The Papp values from the Caco-2 experiments and the
partition coefficients from the membrane affinity experiments yielded similar information on the
biomembrane interactions of flavonoids [V], i.e. strong membrane affinity was generally
accompanied by poor apical to basolateral transport in Caco-2 cells. Thus, at least with these model
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compounds, the membrane affinity experiments would have been a good predictor of a compound’s
permeability characteristics and a useful tool to replace the tedious Caco-2 model. Even though it is
possible to perform the Caco-2 experiments in miniaturised formats such as 24- and 96-well
density (unpublished results), the throughput of the assay, including HPLC analysis of the samples,
is still much more laborious. As it is significantly faster to perform, the biochemical membrane
affinity assay could be considered as an alternative for eliminating compounds with undesirable
characteristics from large compound pools.
6.3. Advances in assay development, throughput and automation
In seeking to improve the throughput of cell-based assays used in bioactivity screening, this study
led to several significant achievements. The miniaturisation of 45Ca2+ uptake in GH4C1 cells from
Petri dish scale to 96-well plate format, and optimisation of the cell culture practice, resulted in a
decrease in culture time from 7 to 3 days and an increase in the number of data points obtained
from one assay from 30 to 60. Furthermore, 80% less cells and 90% less reagents are needed
compared to the Petri dish assay, which means substantial savings, including in the use of 45Ca2+
[II, Table 1]. Developing a 96-well plate assay (TR-FIA) for screening antichlamydial activity
meant valuable improvements to the traditional 24-well plate assay based on IF staining (Table 6).
The miniaturisation from 24-well to 96-well format resulted in significant savings in cell amounts
and use of C. pneumoniae inoculum, while at the same time increasing the number of data points
obtainable from one experiment 2.5-fold.
Table 6. Summary on the benefits achieved through assay miniaturisation and automation for
screening of antichlamydial activity.
Assay conditions TR-FIA IF staining
Assay volume (µl) 200 1000
Cell amount 60,000 400,000
Use of C. pneumoniae inoculum
(IFU/well)
14,000 80,000
Data points per assay 60 24
Analysis time 3 min hours
Number of steps exploiting
automation*
8 -
*here the automation is considered as the use of multichannel and multidose pipettors and stand-
alone devices in sample handling
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The objectivity of the TR-FIA is also a great benefit compared to IF staining. In the TR-FIA,
several steps in the assay protocol are automated and enable the handling of multiple samples
simultaneously, making the protocol far less tedious than IF staining and PCR. Owing to the use of
a multilabel counter, the results of one plate in the TR-FIA can be obtained significantly faster than
with conventional IF staining (Table 6).
Automation of liquid handling operations and other steps in the assay protocol is one of the key
requirements in HTS assays (Oldenburg et al. 2001). In the present study, the assay for 45Ca2+
uptake in GH4C1 cells was shown to be suitable for automated operation by a liquid handling
device [II]. In the manual version, liquid handling was based on multichannel pipetting, which
already enabled the simultaneous handling of parallel samples. The automation was taken further
by introducing the assay to an automated environment in which the pipetting steps were performed
with a 96-channel pipetting head. The experiments performed on a Biomek FX workstation
demonstrated that when a manually operated assay is taken to an automated platform, the protocol
needs to be carefully re-evaluated and optimised [II]. Clearly, liquid handling plays a critical role
in the performance of automated cell-based assays.
The coupling of the automated 45Ca2+ uptake assay to analytical HPLC micro-fractionation greatly
facilitates the classical process leading from a plant to a pharmacologically active, pure constituent
[III]. Using HPLC micro-fractionation, components of crude extracts can be divided into fractions,
collected into micro-well plates and subjected to diverse bioassays to examine properties such as
enzyme inhibition or antimicrobial effects (Hamburger 2003, Wennberg et al. 2004). With this
approach the observed bioactivity can be connected to the biologically relevant component by
identifying it from the chromatogram on the basis of the bioactivity profile obtained, avoiding the
isolation of inactive compounds. One notable benefit in the automation suitability of the integrated
assay, in addition to the reduction in work-load, is the fact that the fractionation is made into 96-
well plates, which are directly compatible with automated liquid handling, and thus the samples can
be taken direct to the assay from the plate with no need for prior sample transfer.
In summary, the development of a screening assay for the evaluation of biological activity is a
process where several decisions need to be considered. Factors connected with the different steps
of the process are presented in Fig. 10.
Basic assay design
Target selection and production
Cell-based / Biochemical assay
Need to complement by e.g. cellular
permeability or toxicity assays
Selection of detection technology
Assay optimisation
Evaluation of assay quality
Assay automation
Compound library
Evaluation of cytotoxicity
Availability of readers
Assay requirements
(e.g. sensitivity, detection limit, speed)
Costs
(e.g. special reagents, labware, label)
Conditions
Plate format/miniaturisation
Reagents, equipment, labware
Requirements of the detection technology
Total cost
Quality parameters (S/B, S/N, Z, Z’)
Selection of positive control
Repeatability and reproducibility
(within-plate, plate-to-plate, day-to-day)
Model compounds
Setting of thresholds for in-process quality
control
Evaluation of automation suitability
•which steps
• what level (multichannel pipettors, liquid
handling
  device, robotics)
•demands set by the needed throughput
Benefits/disadvantages
Evaluation of impact on costs
Performance compared to manual
Identification of false positives
Assay selection
(e.g. metabolic activity, dye uptake, cell
proliferation)
Possibility to integrate to the bioassay
Pure compounds
Extracts
•possibility to integrate HPLC
  micro-fractionation to the bioassay
•integrated compound identification
Figure 10. Scheme on the factors involved in assay development for preclinical screening process in academic settings.
Data management
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6.4. Quality parameters in assay development and validation
Special requirements are set on assays used for bioactivity screening, particularly on those used in
HTS. Most of all, the assays need to be robust, reproducible and suitable for automation
(Sittampalam et al. 1997a, Zhang et al. 1999). A simple way to evaluate these features is to use the
quality parameters S/B, S/N and Z’ factor. When isolated targets were employed, as in PKC assays
[I], values of S/B 47.4, S/N 15.9, and Z’ 0.73 for the [3H]-phorbol ester binding assay were
obtained (Table 7). The day-to-day variation of the assay was 3.7%, indicating good
reproducibility. In the case of cell-based assays, the biological variation has an impact and lower
values are typical (e.g. the cell-based 45Ca2+ uptake assay yielding S/B 3.9, S/N 10.3, and Z’ 0.59,
and day-to-day variation of 5.0%, Table 7). As shown by the results, the response obtainable in
cellular experiments can have limitations (e.g. the S/B ratio can be weaker), and in fact even when
similar cell lines and reporter gene constructs are utilised, the activities measured can be
significantly different (Zhang et al. 1999). Moreover, in the case of a highly complex assay system
such as chlamydial infection in HL cells in the TR-FIA [IV], the values are further affected (S/B
6.5, S/N 6.9, Z’ 0.39, and day-to-day variation 9.0%).
Table 7. Summary of the values obtained for the quality parameters [I, II, IV].
Assay S/B S/N Z’ Day-to-day
variation (%)
Kinase activity 16.1 11.3 0.62 10.1
[3H]-Phorbol ester binding 47.4 15.9 0.73 3.7
45Ca2+ uptake 3.9 10.3 0.59 5.0
TR-FIA 6.5 6.9 0.39 9.0
The assay quality also depend greatly on the detection technique employed in the assay. The
increase in signal obtained with a good label and a suitable detection technique can significantly
improve the difference between the signal of interest and the interfering background, the result
being better assay performance in terms of the quality parameters. There are several alternative
technologies, each of which has certain advantages. One of these is TRF, in which lanthanide
chelates are used to enable separation of autofluorescence relating to cells from the actual signal
(Soini and Kojola 1983, Hemmilä et al. 1984). This approach was found to be a powerful tool in
developing the TR-FIA for screening of antichlamydial activity [IV]. Discrimination between
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infected and non-infected cells was not possible using a fluorescein isothiocyanate-labelled
antibody due to the weakness of the signal and the interfering host cells, whereas a good S/B ratio
was obtained by exploiting a europium-labelled antibody. Through detailed optimisation of
labelling conditions, the quality of the assay was further enhanced. The choice of detection
technique and conditions can thus have a major impact on the quality of the assay.
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7. CONCLUSIONS
Assay development for bioactivity screening has strong impacts on the final outcome of the whole
drug discovery process. The present study focused on several aspects related to assay design and
quality with the aim of setting up a panel of assays for performing bioactivity screening in an
academic setting.
When developing a bioassay, careful consideration must be given to several issues that may affect
the quality of the assay. Depending on the target, the complexity of its function and other factors,
one of the biggest decisions is the choice between biochemical and cell-based screens. This study
utilised both enzyme- and cell-based assays, each of which has certain benefits. The protein kinase
C assays clearly showed that one important advantage of assays exploiting isolated targets over
cell-based assays is their better reproducibility. Secondly, in cell-based assays, the cell culture
infrastructure will certainly limit the sample throughput rate. On the other hand, cellular formats
yield biologically more relevant information on efficacy, e.g. direct effects on Ca2+ channels in
GH4C1 cells, and simultaneous observation of a compound’s cytotoxicity. The biomembrane
experiments with flavonoids and alkyl gallates showed that in certain situations there are potential
alternative ways to examine the biological function. The relevance of information from more
laborious and time-consuming cell-based assays needs to be thoroughly considered on a case-by-
case basis.
Another central decision in assay design is the choice of detection technique. Advances in the
development of detection methods have significantly boosted the use of more complex cell-based
assays at early stages in bioactivity screening programmes. Radiometric labelling, although being
used less and less because of safety and health concerns, has the ability to yield high S/B ratios and
is more suitable for certain assay types than fluorescence-based methods, e.g. for the PKC and
45Ca2+ uptake assays in this study. Then again, the diversity of sophisticated fluorometric methods
offers multiple opportunities to overcome many problems associated with cell-based assays. The
unique properties of time-resolved fluorometry enabled us to design a miniaturised cell-based
immunoassay, TR-FIA, for screening antichlamydial activity. Using this approach the assay was
miniaturised from 24- to 96-well format, thus enabling the simultaneous handling of multiple
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samples, automated washing after staining, and, most importantly, plate reader-based detection as
well as simultaneous cytotoxicity testing.
Detailed optimisation of assays can lead to a significant improvement in assay quality such as
stronger signals in immunoassays, and it is therefore important to find the optimum assay
conditions and cell culture procedures. During assay development, the repeatability and
reproducibility need to be ascertained by determining within-plate, plate-to-plate and day-to-day
variations. The quality parameters S/B, S/N, and Z’ are a valuable set of tools in bioactivity
screening. In assay development, different assay conditions can easily be compared in relation to
the quality of the data obtained. Also, during the screening phase, the reliability of the data can be
checked by monitoring the values of quality parameters from individual experiments.
In terms of saving time and money, the miniaturisation of assays by changing to high-density plate
formats facilitates the screening of large compound libraries. However, this often necessitates a
higher degree of assay automation when the manual handling of plates and reagent additions
become impossible. In the case of cell-based assays, moving to automated assay format requires
additional optimisation of assay design, as we clearly evidenced during automation of the 45Ca2+
uptake measurement. In our studies, the automated assay was further coupled with HPLC micro-
fractionation, helping us to identify calcium antagonist components in a root extract of
Peucedanum palustre and excluding the preparative chromatographic separation previously
needed.
The achievements of this study in terms of assay development, miniaturisation and automation will
certainly be useful for evaluating PKC inhibitory, calcium antagonistic and antichlamydial
activities as well as the biomembrane interactions of test compounds. Most importantly, the
knowledge gained from developing and optimising the bioassays will be beneficial for setting up
bioactivity screening projects in academic settings.
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